Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 8714. Отображено 100.
05-02-2019 дата публикации

Аппликатор для введения ректальной свечи

Номер: RU0000186840U1

Полезная модель относится к технической области медицинских инструментов и может быть использована в качестве инструмента для самостоятельного ректального введения лекарственных свечей, а для медицинских учреждений - одноразового инструмента того же назначения. Аппликатор содержит полый цилиндрический корпус со сквозным проходом, фланцем на нерабочем конце и сопряженным с корпусом подвижным опорным диском. Внутренний диаметр цилиндрического корпуса выполнен меньшим наибольшего диаметра предполагаемой для введения свечи. Размещенный в корпусе шток-поршень выполнен в виде штока с диском-толкателем, диаметр которого равен внутреннему диаметру корпуса, с ограничителем перемещения штока, выполненным в виде диска, установленного от наружного торца диска-толкателя на расстояние равное длине корпуса, и с нажимным диском на конце штока. Ограничитель перемещения штока может быть выполнен также в виде штифта, а опорный диск, установленный на корпусе, выполнен фрикционно-подвижным. Для удержания конической свечи от выхода после введения, свечу в отверстии входной части корпуса аппликатора следует закреплять за ее часть с большим диаметром. Технический результат заключается в возможности изготовления заявляемого аппликатора с использованием материалов технологии, и оборудования для серийного производства одноразовых шприцов. 1 з.п. ф-лы, 3 ил. РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 186 840 U1 (51) МПК A61M 31/00 (2006.01) A61M 37/00 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ ПОЛЕЗНОЙ МОДЕЛИ К ПАТЕНТУ (52) СПК A61M 31/00 (2018.08); A61M 37/00 (2018.08) (21)(22) Заявка: 2018139142, 06.11.2018 (24) Дата начала отсчета срока действия патента: (73) Патентообладатель(и): Шолин Юрий Александрович (RU) Дата регистрации: 05.02.2019 (56) Список документов, цитированных в отчете о поиске: RU 78674 U1, 10.12.2008. RU 180349 U1, 08.06.2018. RU 11075 U1, 16.09.1999. RU 172024 U1, 26.06.2017. (45) Опубликовано: 05.02.2019 Бюл. № 4 1 8 6 8 4 0 (54) АППЛИКАТОР ...

Подробнее
16-02-2012 дата публикации

System and methods for the production of personalized drug products

Номер: US20120041778A1
Автор: Daniel L. Kraft
Принадлежит: Individual

A system and method for determining an optimal combination drug product for a particular patient includes a processor that receives patient information and determines an optimal combination drug product based on the received information. A system which can provide information regarding predicted events or pathologies based on received patient information and guidance on subsequent steps to ameliorate, treat or intervent. A drug production device includes a plurality of drug containers, each of which are coupled to a drug dispensing channel. A controller controls the dispensing of drug through each channel, and a combination drug product is produced from the dispensed drugs. A combination drug product includes a plurality of discrete units of a first drug, and a plurality of discrete units of a second drug. A transdermal patch includes a plurality of drug compartments, each containing a quantity of drug product, and a controller for controlling the release of drugs from each compartment. Feedback loop elements can enable iterations to optimized personalized doses.

Подробнее
10-05-2012 дата публикации

Modular ingestible drug delivery capsule

Номер: US20120116358A1
Принадлежит: KONINKLIJKE PHILIPS ELECTRONICS NV

An ingestible capsule ( 10 ) is provided for delivery of a drug, the capsule ( 10 ) comprises a first module ( 11 ) and a second module ( 12 ). The first module ( 11 ) has at least one drug compartment ( 13 ) for comprising an amount of the drug. The drug compartment ( 13 ) is sealed by a foil ( 14 ) with an embedded conducting heating wire ( 15 ). The second ( 12 ) module comprises electronics ( 18 ) for providing an electrical pulse to the heating wire ( 15 ) in order to open the drug compartment ( 13 ) by melting the foil ( 14 ). The first module ( 11 ) and second module ( 12 ) comprise interoperable connection means ( 19 ) for securing the first module ( 11 ) to the second module ( 12 ) such that the heating wire ( 15 ) is electronically coupled to the electronics ( 18 ).

Подробнее
13-12-2012 дата публикации

Band seal-preparation liquid viscometer for capsules

Номер: US20120312449A1
Принадлежит: Qualicaps Inc

The present invention is directed to an apparatus for controlling the absolute viscosity of band seal-preparation liquid in a process to apply the band seal-preparation liquid to seal two part capsules comprising a) a first source comprising a band seal-preparation liquid, a second source comprising purified water, a loop connected from said first source, wherein said loop is connected to the first source, and wherein said band seal-preparation liquid is circulated in one direction through said loop from said first source back to said first source; and an apparatus for measuring the absolute viscosity of said band seal-preparation liquid in said loop to produce a absolute viscosity measurement, and applying the band seal-preparation liquid to a two part capsule in order to create a seal band to seal the two parts together.

Подробнее
07-02-2013 дата публикации

Device for filling soluble containers with an improved assembly for orienting and filling capsules

Номер: US20130032246A1
Принадлежит: Raj Vikram Tahil

A device for filling soluble containers is provided. The device includes an assembly for orienting capsules comprising a sheet component having a top sheet, a bottom sheet and a sliding sheet adapted to move between the top and bottom sheets. The top sheet includes slots for accommodating capsules, and the bottom sheet includes notches adapted to orient the capsules into a filling position. In a first position, the slots in the sliding sheet align with the slots in the top sheet. In a second position, the slots in the sliding sheet align with the notches in the bottom sheet. The assembly also includes a base component for guiding the oriented capsules therethrough. The base component can have an antistatic sheet fastened to the bottom surface. The sheet component can be loose fitted to the base component. An assembly for filling capsules is also provided.

Подробнее
28-02-2013 дата публикации

Anti-clog suction tip apparatus and methods

Номер: US20130053828A1
Принадлежит: Individual

Various forms of anti-clog suction tips apparatus are disclosed. For example, an anti-clog suction tip apparatus includes a suction tip assembly having a suction tip with a suction opening at a first end thereof for removing debris through suction, a hose attachment portion for attaching the suction tip assembly to a suction source, and an ejection wire channel. The apparatus further includes an ejection wire assembly having an ejection wire extending within the channel and an ejection button integral with or connected to the ejection wire. Applying a force to the ejection button advances the ejection wire through the channel such that an end portion of the ejection wire enters the suction tip and dislodges debris clogging the suction tip. The ejection wire may include an enlarged end portion such as, for example a ball tip. One or more of the components of the apparatus may be single-use and disposable.

Подробнее
14-03-2013 дата публикации

ENTERAL FEEDING AND REFLUX COLLECTION SYSTEM AND METHOD USING VENTED SYRINGE

Номер: US20130066260A1
Принадлежит: NEOMED, INC.

An enteral fluid delivery and reflux collection system and method are disclosed. A fluid nutrient source container and administration tube are joined to an enteral feeding tube, and a gastric reflux tube connects a vented reflux collection syringe to selectively permit or prevent reflux collection, and/or to aspirate or flush the associated fluid lines. 1. An enteral reflux collection system comprising:a fluid container comprising a discharge;an enteral feeding tube for delivering fluid from the fluid container;a vented reflux collection syringe; anda reflux relief tube for delivering reflux to the vented reflux syringe, the reflux relief tube being coupled with respect to the enteral feeding tube.2. The enteral reflux collection system of claim 1 , wherein the vented reflux collection syringe is configured to be positioned at a higher elevation than the fluid container discharge.3. The enteral reflux collection system of claim 1 , further comprising a coupling to couple the reflux relief tube and the enteral feeding tube.4. The enteral reflux collection system of claim 3 , wherein the coupling comprises a Y-connector.5. The enteral reflux collection system of claim 1 , wherein the vented collection syringe comprises an internal elongate cavity and a plunger claim 1 , the plunger being translatably secured within the internal elongate cavity.6. The enteral reflux collection system of claim 1 , wherein the vented collection syringe comprises an internal elongate cavity and at least one elongated channel vent.7. The enteral reflux collection system of claim 1 , wherein the vented collection syringe comprises a plunger comprising a sealing head configured to create a vacuum within the vented collection syringe.8. The enteral reflux collection system of claim 7 , wherein the vented collection syringe comprises at least one vent configured to release the vacuum when aligned with the plunger sealing head.9. The enteral reflux collection system of claim 1 , wherein the ...

Подробнее
28-03-2013 дата публикации

ENCAPSULATION DEVICE, MEDICAL CAPSULES, AND ENCAPSULATION METHOD

Номер: US20130078308A1
Принадлежит: SEIKO EPSON CORPORATION

An encapsulation device includes: a fluid injection device that injects a first liquid forming a core; a liquid film holder that holds in film form a second liquid forming a shell containing the core; and a liquid contact device that makes the shell in contact with a third liquid, in which the first liquid is injected toward a liquid film of the second liquid retained by the liquid film holder to form a core, the core is wrapped with the second liquid on passing through the liquid film of the second liquid, thereby forming the shell, and the shell is made in contact with the third liquid to induce chemical reaction. 1. An encapsulation device comprising:a fluid injection device that injects a first liquid forming a core;a liquid film holder that holds in film form a second liquid forming a shell containing the core; anda liquid contact device that makes the shell in contact with a third liquid,the first liquid being injected toward a liquid film of the second liquid retained by the liquid film holder to form a core,the core being wrapped with the second liquid on passing through the liquid film of the second liquid, thereby forming the shell, andthe shell being made in contact with the third liquid to induce chemical reaction.2. The encapsulation device according to claim 1 , whereinthe liquid contact device has a liquid reservoir that reserves the third liquid in liquid form, andthe second liquid is made in contact with the third liquid by making the core wrapped with the second liquid to enter the liquid reservoir.3. The encapsulation device according to claim 1 , whereinthe liquid contact device has a mist generator that mists the third liquid in mist form, andthe second liquid is made in contact with the third liquid by misting the third liquid from the mist generator to an area, toward which the core wrapped with the second liquid is moved.4. The encapsulation device according to claim 2 , whereinthe second liquid is an aqueous solution containing a ...

Подробнее
28-03-2013 дата публикации

Modular Drug Delivery System for Minimizing Trauma During and After Insertion of a Cochlear Lead

Номер: US20130079749A1
Принадлежит: ADVANCED BIONICS, LLC

A modular capsule includes a first therapeutic agent having a first solubility in biological fluids in an implanted environment and a second therapeutic agent having a second lower solubility in the biological fluids. The modular capsule is configured such that dissolution of the first therapeutic agent increases a rate of dissolution of the second therapeutic agent. 1. A modular capsule comprising:a first therapeutic agent with a first solubility in biological fluids in an implanted environment;a second therapeutic agent with a second lower solubility in the biological fluids;in which dissolution of the first therapeutic agent increases a rate of dissolution of the second therapeutic agent.2. The modular capsule of claim 1 , wherein the first therapeutic agent is interposed between the second therapeutic agent and the biological environment.3. The modular capsule of claim 1 , further comprising:a wall surrounding the first therapeutic agent and the second therapeutic agent; andan aperture through the wall exposing a surface of the first therapeutic agent.4. The modular capsule of claim 3 , wherein a layer of the first therapeutic agent is interposed between the aperture and a layer of the second therapeutic agent.5. The modular capsule of claim 3 , wherein the aperture is covered by a permeable membrane.6. The modular capsule of claim 1 , first therapeutic agent is contained within a metal foam exposed to biological fluids on a first side claim 1 , wherein the second therapeutic agent is disposed adjacent to a second side of the metal foam.7. The modular capsule of claim 6 , wherein dissolution of the first therapeutic agent opens pores in the metal foam.8. The modular capsule of claim 1 , wherein dissolution of the first therapeutic agent exposes a surface area of the second therapeutic agent to the biological fluids claim 1 , the surface area remaining substantially constant as the second therapeutic agent dissolves.9. The modular capsule of claim 1 , wherein the ...

Подробнее
28-03-2013 дата публикации

APPARATUSES AND METHODS FOR MEDICATION ADMINISTRATION

Номер: US20130079750A1
Автор: JR. Bradford, Macy
Принадлежит:

A method of delivering medication to a patient includes inserting a medication administration device into a rectum of the patient, inflating a balloon of the medication administration device to retain the medication administration device in the rectum, delivering a first dose of a medication through the medication administration device such that the first dose of medication is applied to a distal portion of the rectum, delivering a second dose of a medication through the medication administration device such that the second dose of medication is applied to the distal portion of the rectum, and leaving the medication administration device in the rectum until it is dislodged for defecation. The first and second doses are delivered without removing the medication administration device from the rectum between doses. 1. A method of delivering medication to a patient comprising:inserting a medication administration device into a rectum of the patient;inflating a balloon of the medication administration device to retain the medication administration device in the rectum;delivering a first dose of a medication through the medication administration device such that the first dose of medication is applied to a distal portion of the rectum;delivering a second dose of a medication through the medication administration device such that the second dose of medication is applied to the distal portion of the rectum, wherein the first and second doses are delivered without removing the medication administration device from the rectum between doses; andleaving the medication administration device in the rectum until it is dislodged for defecation.2. The method of claim 1 , wherein the medication administration device comprises a tube and a plurality of holes extending through a wall of the tube claim 1 , and wherein inserting comprises inserting the medication administration device such that the holes are positioned in the distal portion of the rectum.3. The method of claim 1 , ...

Подробнее
04-04-2013 дата публикации

Tight sealing of filled medicament capsules

Номер: US20130081358A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

The present invention relates to a method, a device, and a control program for the fluid-tight sealing of capsules containing medicaments, wherein the capsules consist of at least one capsule body and a capsule cap which are set one into the other telescopically and provided with a tight band in the abutment region on the exterior side of the capsule, wherein the capsule components are filled with gas which has a changed temperature and/or a changed pressure in relation to the environment, and wherein a reduction of the difference in pressure in the capsule to occurs via gaps between capsule body and capsule cap after the capsule components have been placed one inside the other. The capsules produced via the method according to the invention are disposable capsules and preferably contain a single dose of an orally administered pharmaceutical formulation in the form of a powder or a liquid. 1. Method for the fluid-tight sealing of capsules containing medicaments , wherein the capsules consist of at least a capsule body and a capsule cap , which are placed telescopically one inside the other and are provided with a leak-tight seal in the gap of the junction on the inside of the capsule or with a sealing band on the outside of the capsule , characterised by the steps of:filling the capsule parts with a gas that is at a different temperature and/or a different pressure from the environment; andallowing a differential pressure reduction in the capsule through gaps between the capsule body and capsule cap after the capsule parts have been fitted together.2. Method according to claim 1 , characterised in that the capsule parts are filled with a gas with a relative reduced pressure of 50 Pa to 5000 Pa.3. Method according to claim 1 , characterised in that the interior of a capsule filling machine is evacuated using a pump.4. Method according to claim 1 , characterised in that the capsules are transported through an airlock chamber out of the capsule filling machine claim 1 ...

Подробнее
04-04-2013 дата публикации

Applicator for Dispensing a Medicinal Substance and Methods Associated Therewith

Номер: US20130085456A1
Принадлежит:

An applicator includes a stem having an axially-formed slot delivery passage . A slot is formed transaxially through the stem and is in communication with the slot delivery passage . An extended side wall is formed on one side of the slot . A flat surface is formed in the stem and extends angularly away from an opposite side of the slot and from the extended side wall to provide a wide slot opening at an external surface of the stem for dispensing a cream from the opening. A trough-like cleft can be formed in the external surface of a solid portion of the stem , distally of the slot , to provide an axially-extended path for the cream being dispensed through the slot. 1. An applicator for dispensing a medicinal substance therethrough , where the substance has a cream-like consistency of the type which does not flow without a force being applied thereto , which comprises:a body formed about an axis which extends from a proximal end of the body to an exterior axial surface of a closed distal end of the body;the body formed with a proximal section which extends from the proximal end of the body toward the closed distal end of the body, and to a distal end of the proximal section;the proximal section of the body formed with an axial entry passage extending through the proximal section from a the proximal end of the body toward a the closed distal end of the body, and to a distal end of the axial entry passage;the axial entry passage being formed with a prescribed diameter at the proximal end of the body;the body being formed with an axial intermediate passage having a proximal end in communication with the distal end of the axial entry passage, and extending toward the closed distal end of the body, and to a distal end of the axial intermediate passage;the axial intermediate passage being formed with a uniform passage diameter which is less than the prescribed diameter;the body being formed about the axis thereof with a passage section, having a uniform exterior diameter ...

Подробнее
18-04-2013 дата публикации

COMPOSITION FOR PREVENTING OR TREATING OSTEOPOROSIS, AND MANUFACTURING METHOD THEREFOR

Номер: US20130096091A1
Принадлежит:

The present invention relates to a composition for preventing or treating osteoporosis which comprises an ibandronic acid, or a pharmaceutically acceptable salt thereof, or a hydrate thereof, and vitamin D. The present invention relates to a composition for preventing or treating osteoporosis which has uniform medicinal effects by minimizing the differences in physical properties between ibandronic acid, or the pharmaceutically acceptable salt thereof, or the hydrate thereof, and vitamin D. 1. A tablet for prevention or treatment of osteoporosis , comprising:a granule including ibandronic acid, a pharmaceutically acceptable salt thereof or hydrates thereof, and having a density of from 0.4 g/mL to 0.7 g/mL; andvitamin D,wherein the tablet contains ibandronic acid, the pharmaceutically acceptable salt thereof or the hydrates thereof in an amount of from 100 mg/tablet to 300 mg/tablet and vitamin D in an amount of from 12,000 IU/tablet to 36,000 IU/tablet.2. (canceled)3. The tablet of claim 1 , wherein the granule is formed using a dry granulation process.45.-. (canceled)6. The tablet of comprising a plurality of granules claim 1 , wherein a 50 wt % or larger portion of the granules ranges in particle size from 30 mesh to 80 mesh.7. (canceled)8. The tablet of claim 1 , further comprising at least one additive selected from among an excipient claim 1 , a lubricant and a disintegrant.9. The tablet of claim 1 , wherein the pharmaceutically acceptable salt is selected from among an ammonium salt claim 1 , an alkali metal salt claim 1 , an alkaline earth metal salt and an amino acid salt.10. (canceled)11. The tablet of claim 1 , wherein the vitamin D is at least one selected from among cholecalciferol claim 1 , calcifediol claim 1 , calcitriol and ergocalciferol.1213.-. (canceled)14. A method of preparing a tablet for prevention or treatment of osteoporosis claim 1 , comprising:granulating ibandronic acid, a pharmaceutically acceptable salt thereof or hydrates thereof to ...

Подробнее
25-04-2013 дата публикации

System and method for mixing the contents of two containers

Номер: US20130102990A1
Принадлежит:

A system for mixing the contents of a first container and a second container. The system includes the first container that has container body with an opening fluidly connected to a cavity defined by the container body, a first substance contained in the cavity, and a stopper sealing the opening. The second container includes a port assembly including a port housing connected to the second container and a retainer constructed to connect to the first container. The retainer is configured to rotate and move axially relative to the port housing, wherein relative rotation between the port housing and the retainer causes the retainer to move axially relative to the port housing. The port assembly further includes an axially fixed actuator constructed to force the stopper into the first container when the retainer is rotated relative to the port housing. 1. A system for mixing the contents of a first container and a second container , the system comprising:a first container comprising a container body comprising an opening fluidly connected to a cavity defined by the container body, a first substance contained in the cavity, and a stopper sealing the opening;a second container having a cavity containing a second substance; anda port assembly comprising a port housing connected to the second container, and a retainer constructed to connect to the first container, wherein the retainer is configured to rotate and move axially relative to the port housing, wherein relative rotation between the port housing and the retainer causes the retainer to move axially relative to the port housing, and wherein the port assembly further comprises an axially fixed actuator constructed to force the stopper into the first container when the retainer is rotated relative to the port housing.2. The system of claim 1 , wherein a first set of threads are formed on a surface of the port housing and wherein a second set of threads are formed-on a surface of the retainer claim 1 , the first and ...

Подробнее
25-04-2013 дата публикации

System and method for mixing the contents of two containers

Номер: US20130102992A1
Принадлежит:

A port assembly for establishing fluid communication between a first container and a second container. The port assembly includes a port housing for connection to a second container, and a retainer for connection to a first container, wherein the retainer rotates relative to the port housing and is constructed to move axially within the port housing. An actuator is axially fixed within the port housing and forces a stopper associated with a first container into a first container when the retainer moves axially within the port housing upon rotation of the retainer relative to the port housing. The assembly is configured to establish fluid communication between a first container and a second container upon rotation of the retainer relative to the port housing. 1. A port assembly for establishing fluid communication between a first container and a second container , the port assembly comprising:a port housing constructed for connection to a second container, the port housing having a first end and a second end;a retainer constructed for connection to a first container, wherein the retainer rotates relative to the port housing, the retainer constructed to move axially within the port housing toward the second end of the port housing upon rotation of the retainer relative to the port housing; andan actuator axially fixed within the port housing, the actuator constructed to force a stopper associated with a first container into a first container when the retainer moves axially within the port housing upon rotation of the retainer relative to the port housing.2. The port assembly of claim 1 , wherein the assembly is configured to establish fluid communication between a first container and a second container upon rotation of the retainer relative to the port housing.3. The port assembly of claim 1 , wherein the port housing comprises first threads and the retainer comprises second complementary threads claim 1 , the first and second threads being constructed to cause the ...

Подробнее
02-05-2013 дата публикации

Enteric Coated Particles Containing An Active Ingredient

Номер: US20130108698A1
Автор: Huang Hugh

Enterically coated particles and chewable tablets made therefrom are disclosed. The enterically coated particles are comprised of a core containing an active ingredient, a first coating layer comprised of polymeric composition having a Tg less than about 40° C. that substantially covers the core; and a second coating layer, which substantially covers the first coating layer, comprised of a high temperature film forming polymer. The particles may be produced into a tablet form, such as a chewable tablet form, that provides for the immediate release of the active ingredient. 134-. (canceled)35. A tablet comprising enterically coated particles , wherein said particles comprise:a) a particle core containing an active ingredient;b) a first layer that substantially covers the core and has a surface; andc) a second layer on the surface of the first layer, wherein the first layer comprises an enteric polymer and has a Tg less than about 40° C. and the second layer comprises an enteric polymer and has a Tg greater than about 56° C., wherein the average diameter of the particle core is from about 30 to about 600 microns.36. The tablet of claim 35 , wherein the second layer substantially covers the first layer.37. The tablet of claim 35 , wherein the first layer is present in an amount claim 35 , based upon the total weight of the coated particle claim 35 , from about 5% to about 50% and the second layer is present in an amount claim 35 , based upon the total weight of the coated particle claim 35 , from about 3% to about 20%.38. The tablet of claim 35 , wherein the first layer is comprised of methacrylic acid-methacrylic acid ester copolymers; cellulose acetate phthalate; polyvinyl acetate phthalate; shellac; hypromellose phthalate; or derivatives claim 35 , copolymers or mixtures thereof.39. The tablet of claim 35 , wherein the first layer is comprised of a methacrylic acid-methylacrylic acid ester copolymer having a mean molecular weight of about 800 claim 35 ,000.40. The ...

Подробнее
02-05-2013 дата публикации

HIGHLY DISPERSIBLE GRANULATE FOR THE PREPARATION OF FORMULATIONS OF HIGH DOSAGE ACTIVE SUBSTANCES AND PROCEDURE FOR OBTAINING HIGH DOSAGE ACTIVE SUBSTANCES THEREOF

Номер: US20130108699A1
Принадлежит:

By mixing ibuprofen and a disaggregating agent, the invention involves using these components in a proportion ranging between 96% and 97% by weight for ibuprofen, and between 3% and 4% for the disaggregating agent, which may be Sodium croscarmellose, Crospovidone or Sodium carboxymethyl starch, as well as a mixture thereof. Following the mixing of the raw materials, the mixture is subjected to compaction, granulation and subsequent compression, in order to finally give the tablet a coating; this leads to a significant cost reduction and a significant reduction in the active principle release time, such that the pharmacological action is very fast in time. 1. Ibuprofen tablet , wherein the ibuprofen participates as the active component mixed with a disaggregating agent , characterised in that the ibuprofen participates in the mixture in a proportion ranging between 96% and 97% , whereas the disaggregating agent participates in a proportion ranging between 4% and 3% , by weight.2. Ibuprofen tablet claim 1 , according to claim 1 , characterised in that the disaggregating agent is one or a mixture of the following components:Sodium croscarmellose.Crospovidone.Sodium carboxymethyl starch (Primogel).3. Procedure for obtaining the ibuprofen tablet of the preceding claims claim 1 , characterised in that claim 1 , following the mixing of said raw materials in the aforementioned proportions claim 1 , said mixture is subjected to the following operational phases:Compaction.Granulation.Compression.Coating.4. Procedure claim 3 , according to claim 3 , characterised in that the compaction phase is performed under dry conditions by means of a refrigerated roller compactor.5. Procedure claim 3 , according to claim 3 , characterised in that the granulation phase is performed in a rotary or rolling granulator claim 3 , with an appropriate sieve.6. Procedure claim 3 , according to claim 3 , characterised in that the compression phase may be performed directly or from the granulated ...

Подробнее
02-05-2013 дата публикации

METHOD FOR PRODUCING SEVERAL INJECTION-MOLDED PARTS

Номер: US20130110030A1
Принадлежит: Theracoat Ltd.

Apparatus and methods for treatment of an internal cavity are provided. The internal cavity is coated with a treatment solution. The treatment solution can include a solidifiable matrix with or without a drug or combination of drugs incorporated therein, or a drug solution without a solidifiable matrix. The treatment solution is coated onto at least a portion of the internal cavity, and acts as a slow-release drug delivery system. 1100-. (canceled)101. A method for preventing cell migration and adherence within an internal cavity during tumor resection so as to substantially prevent new cancerous growth , comprising steps of: i. a hydrogel-based biocompatible elastic adhesion substance comprising an agent adapted to increase adherence of a treatment solution to an internal wall of said internal cavity, said hydrogel-based biocompatible elastic adhesion substance adapted to conform to anatomical morphology of said internal wall;', 'ii. at least one treatment solution comprising at least one drug carrier polymeric material selected from the group consisting of polvinylpyrrolidone (PVP) with water as a solvent, polyethylene glycol (PEG) with water as a solvent, and any combination thereof; and a cancer-fighting drug;', 'iii. a buffering polymer for controlling concentration of said cancer-fighting drug reaching said internal wall of said internal cavity, said buffering polymer selected from the group consisting of polyurethanes, polyethylene terephthalate, polyactones, polycaprolactone, polyacrylonitrile, polyethylene glycol and any combination thereof; and,', 'iv. a blocking polymer for controlling the concentration of said cancer-fighting drug reaching said inner volume of said internal cavity; said blocking polymer selected from the group consisting of polyvinylchloride, polyurethanes, polyanhydride, polyethylene glycol and any combination thereof;, 'a. forming a drug carrier by incorporating into a hydrogel based biocompatible matrix each of the following ...

Подробнее
09-05-2013 дата публикации

Burst Drug Release Compositions

Номер: US20130116327A1
Принадлежит: WYETH LLC

A solid dose composition comprising at least one pharmaceutically active ingredient and at least one controlled release agent and method of manufacturing said composition is disclosed. The burst profile of at least one pharmaceutically active ingredient in the composition is regulated by the apparent viscosity of the controlled release agent and wherein at least one pharmaceutically active ingredient is processed by wet granulation. 1. A solid dose composition comprising at least one pharmaceutically active ingredient and at least one controlled release agent wherein the burst profile of at least one pharmaceutically active ingredient is regulated by the apparent viscosity of the controlled release agent and wherein at least one pharmaceutically active ingredient is processed by wet granulation.2. A method of manufacturing a solid dose composition comprising at least one pharmaceutically active ingredient and at least one controlled release agent wherein the burst profile of at least one pharmaceutically active ingredient is regulated by the apparent viscosity of the controlled release agent and wherein at least one pharmaceutically active ingredient is processed by wet granulation.3. A solid dose composition comprising at least one pharmaceutically active ingredient and at least one controlled release agent wherein the apparent viscosity of the controlled release agent is between 100 and 100 ,000 centipoise and wherein at least one pharmaceutically active ingredient is processed by wet granulation.4. A solid dose composition of wherein at least one of the pharmaceutically active ingredients is ibuprofen.5. A solid dose composition of wherein at least one of the controlled release agents is hydroxypropylmethylcellulose.6. A solid dose composition of wherein at least one of the controlled release agents is hydroxypropylmethylcellulose and wherein at least one of the pharmaceutically active ingredients is ibuprofen.7. A method of manufacturing a solid dose composition ...

Подробнее
16-05-2013 дата публикации

ABUSE RESISTANT DRUG FORMULATION

Номер: US20130122087A1
Принадлежит: CIMA LABS INC.

A pharmaceutical composition may include a granulate which may include at least one active pharmaceutical ingredient susceptible to abuse by an individual mixed with at least two materials, a first material that is substantially water insoluble and at least partially alcohol soluble and a second material that is substantially alcohol insoluble and at least partially water soluble, wherein the active pharmaceutical ingredient and the two materials are granulated in the presence of water and alcohol. The composition may also include a coating on the granulate exhibiting crush resistance which may have a material that is deposited on the granulate using an alcohol based solvent. The composition further comprises a second particle comprising a fat/wax. The present invention also includes a coated granulate, various dosage forms of the composition, as well as methods of production and tableting. 122-. (canceled)23. A method of making a tablet comprising:combining an at least one active pharmaceutical ingredient susceptible to abuse by an individual in an amount between about 0.1 to about 90 percent by weight of the granulate mixed with at least two materials, said at least two materials comprise a first material that is substantially water insoluble and at least partially alcohol soluble and is present in an amount between about 1 to about 90 percent by weight of the granulate and a second material that is substantially alcohol insoluble and at least partially water soluble and is present in an amount between about 1 and about 90 percent by weight of the granulate, wherein the active pharmaceutical ingredient and the two materials are granulated in the presence of at least one solvent, forming a wet granulate;milling and drying the wet granulate to form a granulate comprising an average particle size of about 50 to about 700 um;depositing a coating on said granulate provided in an amount of between about 20 and about 75 percent by weight of the coated granulate ...

Подробнее
16-05-2013 дата публикации

TABLET FORMULATIONS CONTAINING 8-[-METHYL]-8-PHENYL-1,7-DIAZA-SPIRO[4.5]DECAN-2-ONE SALTS AND TABLETS MADE THEREFROM

Номер: US20130122088A1
Принадлежит: OPKO Health, Inc.

Pharmaceutical formulations containing a salt of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one, represented by Formula I, which are suitable for forming into a tablet dosage form, as well as tablet dosage forms are disclosed. Disclosed also are methods of treatment utilizing such dosage forms. 1) a powdered pharmaceutical formulation comprising: (a) a granulate comprising at least one crystalline salt of formula I , intragranular microcrystalline cellulose , lactose monohydrate , a first disintegrant , and a binder; and dry-blended therewith (b) extragranular microcrystalline cellulose , a second disintegrant , and magnesium stearate , wherein the formulation provides , upon compression in a tablet press , a pressed tablet having a hardness of at least 10kp.2) the formulation of wherein said first and said second disintegrant are croscarmellose sodium.3) the formulation of wherein said binder is selected from providone k30 claim 1 , pregelatinized starch and hypromellose 2910 claim 1 , 6cps.4) the formulation of wherein: (a) when the binder used to form the granulate is starch it is used in an amount the provides the product formulation with from about 10 wt. % to about 20 wt. % starch; (b) when the binder used to form the granulate is providone k30 it is used in an amount that provides the product formulation with from about 3 wt. % to about 10 wt. % of providone k30; and (c) when the binder used to form the granulate is hypromellose 2910 claim 3 , 6cps claim 3 , it is used in an amount that provides the product formulation with from about 3 wt. % to about 6 wt. % of hypromellose 2910 claim 3 , 6 cps.5) a granulate comprising a crystalline hydrochloride salt of (5s claim 3 ,8s)-8-[{(1R)-1-(3 claim 3 ,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1 claim 3 ,7-diazaspiro[4.5]decan-2-one claim 3 , intragranular microcrystalline cellulose claim 3 , lactose monohydrate claim 3 , intragranular ...

Подробнее
16-05-2013 дата публикации

Multiple Unit Tablet Composition

Номер: US20130122090A1
Принадлежит: Lupin Limited

A multiple unit tablet composition comprising an enteric coated multiple unit cores comprising a pharmaceutically active ingredient, wherein plasticizer content of enteric coating is less than about 10% by weight of the enteric coating polymer; at least two diluents and optionally one or more other pharmaceutically acceptable excipient, wherein one diluent is highly compactable microcrystalline cellulose and process for preparing the same. 1. A multiple unit tablet composition comprises:(i) enteric coated multiple unit cores comprising a pharmaceutically active ingredient, wherein plasticizer content of enteric coating is less than about 10% by weight of the enteric coating polymer;(ii) atleast two diluents and optionally one or more other pharmaceutically acceptable excipient, wherein one diluent is highly compactable microcrystalline cellulose.2. The multiple unit tablet composition according to claim 1 , wherein the pharmaceutically active ingredient is a benzimidazole derivative.3. The multiple unit tablet composition according to claim 2 , wherein the benzimidazole derivative is a proton pump inhibitor.4. The multiple unit tablet composition according to claim 1 , wherein said multiple units comprises separating layer(s) between the core and the enteric coating layer.5. The multiple unit tablet composition according to claim 1 , wherein one diluent is selected from confectioner's sugar claim 1 , compressible sugar claim 1 , dextrates claim 1 , dextrin claim 1 , dextrose claim 1 , fructose claim 1 , lactitol claim 1 , mannitol claim 1 , sucrose claim 1 , starch claim 1 , lactose claim 1 , xylitol claim 1 , sorbitol claim 1 , talc claim 1 , microcrystalline cellulose claim 1 , calcium carbonate claim 1 , calcium phosphate dibasic or tribasic claim 1 , calcium sulphate claim 1 , or combinations thereof.6. The multiple unit tablet composition according to claim 1 , wherein one or more pharmaceutically acceptable excipient selected from binders claim 1 , diluents ...

Подробнее
16-05-2013 дата публикации

Use Of Polyether-Based And Vinyl Monomer-Based Copolymers As Binders For Dosing Forms Comprising Solid Active Ingredients

Номер: US20130123373A1
Принадлежит: BASF SE

The use of water-soluble or water-dispersible copolymers which are obtained by free radical-initiated polymerization of a mixture of 2. The process according to claim 1 , wherein the binder is mixed dry with the active pharmaceutical ingredients and optionally the further pharmaceutical excipients to form a dry mixture claim 1 , and the dry mixture is converted into the solid pharmaceutical dosage form.3. The process according to claim 2 , wherein the binder is incorporated in the form of granules into the solid pharmaceutical dosage form.4. The process according to claim 3 , wherein the granules are obtained by wet granulation claim 3 , fluidized-bed granulation claim 3 , or sinter granulation.5. The process according to claim 3 , wherein further pharmaceutical excipients are incorporated into the granules.6. The process according to claim 3 , wherein active pharmaceutical ingredients are incorporated into the granules.7. The process according to claim 1 , wherein the mixture of the binder claim 1 , the active pharmaceutical ingredients and the optionally further pharmaceutical excipients is converted by compression into the solid pharmaceutical dosage form. This application is a divisional of U.S. patent application Ser. No. 13/120,598, filed Sep. 21, 2009, which is a 371 of International Application Ser. No. PCT/EP2009/062199 filed Sep. 21, 2009, which claims the benefit of European Application Ser. No. 08165113.5 filed Sep. 25, 2008, all of which are incorporated herein by reference in their entireties.The present invention relates to the use of copolymers which are obtained by polymerizing vinyl acetate and N-vinyllactams in the presence of a polyether as binders, especially as dry binders, for solid active ingredient-containing dosage forms, especially tablets.Binders improve the compressibility of active ingredient-containing formulations to solid dosage forms by improving the particle adhesion.Criteria for the standard of quality when testing compressed ...

Подробнее
30-05-2013 дата публикации

High Content Sodium Ibuprofen Granules, Their Preparation and Their Use in Preparing Non-Effervescent Solid Dosage Forms

Номер: US20130136793A1
Принадлежит: Albemarle Corporation

Disclosed is a method for the preparation of easily-swallowed, reliably-dosed, aesthetically-improved tablets of sodium ibuprofen dihydrate, the method comprising the formation of the tablets with punches or presses comprising contact surfaces which are chrome or chrome-plated. 1. A process for forming tablets of sodium ibuprofen dihydrate , said process comprising forming tablets in a press comprising chrome contact surfaces , from granules of sodium ibuprofen dihydrate , the granules having been formed by a process comprising the steps ofbringing together in a low shear, high shear or fluidized-bed granulator components comprised of (i) at least 80 parts by weight on a dry basis of sodium ibuprofen dihydrate, (ii) 1 to 4 parts by weight on a dry basis of sodium carbonate, (iii) 1 to 15 parts by weight on a dry basis of non-crosslinked polyvinylpyrrolidone, and (iv) 8 to 12 parts by weight of water based on the total weight of (i), (ii), (iii), and (iv) to form a wet mixture;granulating said wet mixture by low shear, high shear or fluidized-bed granulation to form wet granules;drying wet granules to form dried granules having a moisture content in the range of about 12.5 to 15 wt % as determinable by measurement of weight loss at 110° C.; andremoving by sieving dried granules having a particle size greater than 16 mesh.2. A process as in wherein the main compression force is in the range of 10 to 20 kilonewtons.3. A process as in wherein the main compression is in the range of about 12 to about 16 kilonewtons.4. A process as in wherein the precompression force in the range of about 0.8 to about 1.0 kilonewtons.5. A process as in wherein the contact surfaces of the punch are chrome-plated.6. A process as in wherein the contact surfaces of the punch are chrome.7. A process as in wherein the punch speed is in the range of about 5 to about 20 RPM.8. A process as in wherein the press comprises a 10-station rotary press comprising chrome contact surfaces.9. A process as ...

Подробнее
06-06-2013 дата публикации

DRUG DELIVERY DEVICE FOR OVARIAN CANCER

Номер: US20130144163A1
Принадлежит: UNIVERSITY OF SOUTH FLORIDA

A drug delivery device has been designed to directly deliver an agent to the ovaries through direct contact with the fallopian tubes. The device consists of three main components: a tubular inserter, a cylindrical chamber and a plunger. The device is a single-use applicator designed in a shape similar to a tampon to facilitate its insertion through the vagina and into the uterus. Positioning of the device centrally in the uterus is accomplished through the use of ultrasound. The chamber is inserted into the tubular inserter. Adjusting the length of the chamber inserted into the tubular inserter controls the amount of tubing released from the apertures in the tubular inserter. Ultrasound is used to ensure the proper placement of each tube at the entrance of each fallopian tube. The plunger is inserted into the chamber and adjustment of the plunger controls the amount of the agent released into the tubes. 1. A drug delivery device comprising:a tubular inserter having a first insertion end and a first opposing end;a pair of apertures disposed in the first insertion end of the tubular inserter;at least one tubing channel disposed within the first insertion end of the tubular inserter wherein the at least one tubing channel terminates at the pair of apertures;a pair of tubes disposed in the at least one tubing channel;a cylindrical chamber having a second insertion end and a second opposing end wherein the cylindrical chamber is slidably received and retained within the first opposing end of the tubular inserter; anda plunger having a third insertion end and a third opposing end wherein the plunger is slidably received and retained within the second opposing end of the cylindrical chamber.2. The drug delivery device of further comprising a tube extension system selected from the group consisting of:a full chamber tubing system wherein the pair of tubes is disposed on the second flange of the cylindrical chamber and extend through the chamber and into the tubing channels; ...

Подробнее
13-06-2013 дата публикации

INTRAVAGINAL RING FOR THE DELIVERY OF UNIQUE COMBINATIONS OF ANTIMICROBIAL COMPOSITIONS

Номер: US20130150810A1
Принадлежит: THE POPULATION COUNCIL, INC.

Disclosed are compositions for inhibiting transmission of a sexually transmitted infection that contain one or more polyanionic microbicides, such as carrageenans, including lambda carrageenan, as well as water-soluble metal salts and specified antiretroviral agents comprising NNRTIs and NRTIs. Also disclosed are methods for making and using the compositions. Also disclosed are intravaginal rings for delivering water-soluble compounds, and preferably high molecular weight water-soluble polymers at essentially a zero order rate. The rings include an outer layer of non-water-swellable elastomer, and preferably high molecular weight water-soluble polymer and an inner layer of the water-soluble polymer, which is imbedded in the outer layer, and an aperture through the outer layer for release thereof only through that aperture. 1. A vaginal ring for the delivery of a water-soluble polymer comprising an outer layer of a non-water-swellable elastomer , an inner layer of said water-soluble compound , and at least one aperture in said outer layer to permit release of said water-soluble compound from said inner layer thereof only through said at least one aperture.2. The vaginal ring of wherein said water-soluble compound comprises a high molecular weight water-soluble polymer.3. The vaginal ring of wherein said outer layer comprises an extruded polymeric ring claim 1 , and said inner layer is encased within said extruded polymeric ring claim 1 , whereby said outer layer comprises the only layer encasing said inner layer.4. The vaginal ring of wherein said non-water-swellable elastomer is capable of controllably diffusing a water-insoluble compound therethrough.5. The vaginal ring of wherein said high molecular weight water-soluble polymer is free of any polymeric coating or layer which will prevent the release of said high molecular weight water-soluble polymer therefrom.6. The vaginal ring of wherein said outer layer comprises an extruded polymeric ring and including a ...

Подробнее
20-06-2013 дата публикации

Devices, Systems and Methods to Detect and Reduce or Prevent Entry of Inflammatory Mediators into Milk Ducts

Номер: US20130158394A1

Devices, systems and methods are disclosed for measurement and reduction or prevention of fluid movement in lactiferous ducts, detection of diseased conditions in the breasts, and treatments thereof. Such techniques, methods and devices are applicable to a variety of conditions including carcinomas. 1. A method for detecting assessing and promoting breast health through an open lactiferous duct , the method comprising:exposing a nipple to a fluid containing a contrast medium;allowing passage of an elapsed period of time; anddetecting the presence of the contrast medium in the lactiferous duct in order to determine if the lactiferous duct is open.2. The method of claim 1 , wherein if the lactiferous duct is determined to be open claim 1 , further comprising:collecting a sample of fluid from the lactiferous duct.3. The method of claim 2 , further comprising:assessing the presence of tumor cells within the collected sample of fluid.4. The method of claim 3 , wherein if tumor cells are detected claim 3 , further comprising:introducing anti-tumor compounds into the lactiferous duct.5. The method of claim 3 , wherein if tumor cells are not detected claim 3 , further comprising:preventing further fluid flow into the lactiferous duct.6. The method of claim 5 , the preventing fluid flow step comprises:sealing the lactiferous duct with glue.7. The method of claim 5 , the preventing fluid flow step comprises:sealing the lactiferous duct via suture.8. The method of claim 5 , the preventing fluid flow step comprises:sealing the lactiferous duct via a cap.9. A milk duct cap comprising:a concave thimble-like inner portion adapted to position over a nipple of a breast; andan outer rim extending from the concave inner portion;wherein the outer rim portion contains an adhesive to adhere to an areola of the breast.10. The milk duct cap of claim 9 , wherein an interior portion of the inner portion contains a non-soluble sealant coating which comes into contact with the nipple.11. The ...

Подробнее
20-06-2013 дата публикации

METHODS AND SYSTEMS FOR EVALUATING THE INTEGRITY OF A UTERINE CAVITY

Номер: US20130158428A1
Принадлежит: Minerva Surgical, Inc.

Methods, systems and devices for evaluating the integrity of a uterine cavity. A method comprises introducing transcervically a probe into a patient's uterine cavity, providing a flow of a fluid (e.g., CO) through the probe into the uterine cavity and monitoring the rate of the flow to characterize the uterine cavity as perforated or non-perforated based on a change in the flow rate. 1. A method of characterizing a patient's uterus , comprising:positioning a probe within a patient's cervical canal and uterine cavity;introducing a flow of a gas through the probe into the uterine cavity; andcomparing a peak inflow rate to subsequent flow rate;characterizing the uterine cavity as either perforated or non-perforated based at least in part on said comparison.2. The method of claim 1 , wherein introducing comprises transcervically introducing the probe into the uterine cavity and introducing the flow through the probe.3. The method of further comprising expanding an ablation device in the uterine cavity.4. The method of wherein introducing comprises introducing the gas at a pre-determined flow rate.5. The method of wherein introducing comprises introducing the gas at an initial flow rate ranging from 0.05 slpm to 0.2 slpm.6. The method of wherein introducing comprises introducing the gas at a pressure ranging from 0.025 psi to 1.0 psi.7. The method of wherein comparing comprises providing a signal responsive at least in part to determining whether the subsequent flow rate drops below the peak flow rate by at least 10% claim 1 , 20% claim 1 , 30% claim 1 , 40% or 50%.8. The method of wherein comparing comprises providing a signal responsive at least in part to determining whether the subsequent flow rate drops to below a value in the range of 0.01 slpm to 0.05 slpm.9. The method of wherein comparing comprises providing the signal with a time interval in the range from 5 second to 30 seconds.10. A method of characterizing a patient's uterus claim 8 , comprising:positioning ...

Подробнее
04-07-2013 дата публикации

ABUSE-PROOFED DOSAGE FORM

Номер: US20130171075A1
Принадлежит: Grünenthal GmbH

The invention relates to a dosage form that is thermoformed without discoloration and is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that could be subject to abuse. The invention also relates to a corresponding method for producing said dosage form. 1. An abuse-proofed dosage form thermoformed by extrusion without discoloration comprising one or more active ingredients with abuse potential (A) , optionally physiologically acceptable auxiliary substances (B) , at least one synthetic or natural polymer (C) and optionally at least one wax (D) , wherein the dosage form exhibits a breaking strength of at least 500 N.2. The dosage form according to claim 1 , which is in the form of a tablet.3. The dosage form according to claim 1 , which contains as polymer (C) at least one polymer selected from the group consisting of polyalkylene oxide claim 1 , polyethylene claim 1 , polypropylene claim 1 , polyvinyl chloride claim 1 , polycarbonate claim 1 , polystyrene claim 1 , polyacrylate claim 1 , copolymers thereof and mixtures thereof.4. The dosage form according to claim 3 , wherein the polyalkylene oxide is selected from the group consisting of polymethylene oxide claim 3 , polyethylene oxide claim 3 , polypropylene oxide claim 3 , copolymers thereof and mixtures thereof.5. The dosage form according to claim 1 , wherein the polymer (C) comprises polyethylene oxide having a molecular weight of at least 0.5 million.6. The dosage form according to claim 5 , wherein the molecular weight of the polyethylene oxide (C) is at least 1 million.7. The dosage form according to claim 6 , wherein the molecular weight of the polyethylene oxide is in the range of from about 1 to about 15 million.8. The dosage form according to claim 1 , which contains the wax (D) claim 1 , and the wax (D) is at least one natural claim 1 , semi-synthetic or synthetic wax with a softening ...

Подробнее
11-07-2013 дата публикации

MANUFACTURE OF LOZENGE PRODUCT WITH RADIOFREQUENCY

Номер: US20130178501A1
Принадлежит: McNeil-PPC, Inc.

The present invention features a process for making a lozenge product including the steps of forming a powder blend containing an amorphous carbohydrate polymer into the desired shape of the lozenge product and applying radiofrequency energy to the shape for a sufficient period of time to soften or melt said amorphous carbohydrate polymer to fuse the shape into said lozenge product. 1. A process for making a lozenge product , said method comprising the steps of forming a powder blend comprising an amorphous carbohydrate polymer into the desired shape of said lozenge product and applying RF energy to said shape for a sufficient period of time to soften or melt said amorphous carbohydrate polymer to fuse said shape into said lozenge product , wherein said powder blend is shaped in a die.2. (canceled)3. The process of claim 1 , wherein said RF energy is applied to said shape within said die.4. The process of claim 1 , wherein said RF energy has a frequency of from about 1 MHz to 100 MHz.5. The process of claim 1 , wherein said amorphous carbohydrate polymer is selected from the group consisting of polydextrose claim 1 , fructo-oligosaccharide claim 1 , galacto-oligosaccharide claim 1 , malto-oligosaccharide claim 1 , isolmalto-oligosaccharide claim 1 , and hydrogenated starch hydrolysate.6. The process of claim 1 , wherein said powder blend comprises nicotine or a salt thereof.7. The process of claim 1 , wherein said powder blend comprises a pharmaceutically active agent.8. The process of claim 1 , wherein said powder blend comprises phenylephrine claim 1 , dextromethorphan claim 1 , pseudoephedrine claim 1 , chlorpheniramine claim 1 , methocarbomal claim 1 , chlophedianol claim 1 , ascorbic acid claim 1 , menthol claim 1 , pectin claim 1 , dyclonine claim 1 , and benzocaine claim 1 , and pharmaceutically acceptable salts thereof.9. The process of claim 1 , wherein said powder blend comprises from about 50 to about 99.9 percent claim 1 , by weight claim 1 , of said ...

Подробнее
18-07-2013 дата публикации

IMMEDIATE RELEASE MULTI UNIT PELLET SYSTEM

Номер: US20130183384A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

The present invention relates to a multiple unit pellet system (MUPS) in form of a tablet containing a pharmaceutically active ingredient, characterized in that the MUPS is an optionally coated immediate release pharmaceutical dosage form for oral administration. 1: A multiple unit pellet system (MUPS) in form of a tablet containing a pharmaceutically active ingredient , wherein the MUPS is an optionally coated immediate release pharmaceutical dosage form for oral administration.2: A pharmaceutical dosage form according to claim 1 , wherein the MUPS tablet comprises a therapeutically and/or prophylactically effective amount of dabigatran etexilate or a pharmaceutically acceptable salt thereof.3: The MUPS tablet according to or wherein the MUPS tablet is uncoated.4: The MUPS tablet according to or having a tablet weight of 100 mg to 600 mg.5: A process for preparing a pharmaceutical composition for oral administration containing a pharmaceutically active substance with pH-dependent solubility characteristics and a dose number of more than 1 at pH>5 or one of the pharmaceutically acceptable salts thereof claim 1 , comprising the steps of:(a) mixing pellets containing active substance with excipients selected from the group consisting of one or more fillers, one or more lubricants, one ore more disintegrants and optionally one or more glidants, and(b) compressing the mixture obtained in step (a) into a tablet.6: The process according to characterized in that the active substance is dabigatran etexilate or a pharmaceutically acceptable salt thereof.7: The process according to claim 6 , wherein the pellets used in step (a) are obtained by a process comprising the steps of:(i) synthesising the core material from one or more pharmaceutically acceptable organic acid(s) with a water solubility of more than 1 g/250 ml at 20° C., optionally with the addition of binders or other technological adjuvants, by pan methods, pelleting plates or by extrusion/spheronisation,(ii) ...

Подробнее
25-07-2013 дата публикации

Wet Granulation Using a Water Sequestering Agent

Номер: US20130189359A1
Автор: Lo Ray J., Sun Thomas
Принадлежит: Rigel Pharmaceuticals, Inc.

Disclosed are tablets comprising hydrolytically stable formulations of (6-(5-fluoro-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-ylamino)-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b][1,4]oxazin-4(3H)-yl)methyl phosphate disodium salt (Compound 1) prepared by a wet granulation process. 1. A wet granulated formulation comprising water , an effective amount of (6-(5-fluoro-2-(3 ,4 ,5-trimethoxyphenylamino)pyrimidin-4-ylamino)-2 ,2-dimethyl-3-oxo-2H-pyrido[3 ,2-b][1 ,4]oxazin-4(3H)-yl)methyl phosphate disodium salt and a sufficient amount of a water sequestering agent to inhibit decomposition of (6-(5-fluoro-2-(3 ,4 ,5-trimethoxyphenyl-amino) pyrimidin-4-ylamino)-2 ,2-dimethyl-3-oxo-2H-pyrido[3 ,2-b][1 ,4]oxazin-4(3H)-yl)methyl phosphate disodium salt , wherein said formulation , after drying , has a bulk density sufficient to form tablets having a hardness in the range of about 6 kp to about 30 kp.2. The formulation of claim 1 , wherein after drying the formulation has a bulk density of between about 0.35 to about 0.65 g/mL.3. The formulation of claim 1 , wherein the water sequestering agent is selected from the group consisting of starch claim 1 , magnesium sulfate claim 1 , calcium chloride claim 1 , silica gel claim 1 , and kaolin.4. The formulation of claim 3 , wherein the water sequestering agent is starch.5. The formulation of claim 4 , wherein the starch is partially pregelatinized.6. The formulation of claim 5 , wherein the starch is derived from Maize.7. The formulation of which further comprises at least one of a filler claim 1 , a lubricant claim 1 , a suspending/dispersing agent claim 1 , a binding agent claim 1 , and a disintegrant.8. A tablet comprising water claim 1 , a therapeutically effective amount of (6-(5-fluoro-2-(3 claim 1 ,4 claim 1 ,5-trimethoxyphenylamino)pyrimidin-4-ylamino)-2 claim 1 ,2-dimethyl-3-oxo-2H-pyrido[3 claim 1 ,2-b][1 claim 1 ,4]oxazin-4(3H)-yl)methyl phosphate disodium salt and a sufficient amount of a water sequestering agent to inhibit ...

Подробнее
01-08-2013 дата публикации

MEDICINE RESERVOIR FOR DRUG DELIVERY DEVICE

Номер: US20130197440A1

A medicine reservoir () is provided for use with a drug delivery device (). The medicine reservoir () is arranged for comprising a drug () and comprises a dispensing hole () for dispensing the drug () into an environment of the drug delivery device (). The medicine reservoir () further comprises a deformable plug () which plug () is removable by pressure caused by a dispensing action of the drug delivery device (). 11050101315135010141450. A medicine reservoir for use with a drug delivery device , the medicine reservoir being arranged for comprising a drug and comprising a dispensing hole for dispensing the drug into an environment of the drug delivery device , the medicine reservoir further comprising a deformable plug which plug is removable by a pressure caused by a dispensing action of the drug delivery device .2101413. A medicine reservoir as claimed in claim 1 , wherein the deformable plug comprises an oil claim 1 , which oil does not mix with the drug or with gastro-intestinal fluid.310. A medicine reservoir as claimed in claim 2 , wherein the oil comprises a mineral oil.410. A medicine reservoir as claimed in claim 2 , wherein the oil comprises castor oil.51031153114. A medicine reservoir as claimed in claim 1 , further comprising a nozzle for partly filling the dispensing hole claim 1 , the nozzle comprising the deformable plug .6. A drug delivery device comprising a medicine reservoir as claimed in .7. A drug delivery device as claimed in claim 6 , further comprising electronics for controlling the dispensing action. This invention relates to a medicine reservoir for use with a drug delivery device, the medicine reservoir being arranged for comprising a drug and comprising a dispensing hole for dispensing the drug into an environment of the drug delivery device.This invention further relates to a drug delivery device comprising such a medicine reservoir.Such drug delivery devices make it possible to control the release of drugs in the gastrointestinal ...

Подробнее
01-08-2013 дата публикации

METHOD AND APPARATUS FOR FORMING DELIVERY DEVICES FOR ORAL INTAKE OF AN AGENT

Номер: US20130197441A1
Принадлежит: Intec Pharma Ltd.

Provided are methods, systems and apparatuses for producing delivery devices, for example, for oral intake of an agent. The method can include assembling one or more layers including one or more materials with an agent or an agent-releasing formulation to form an intergraded device; folding the intergrated delivery device to form a folded integrated delivery device; and at least partially enclosing the folded delivery device to a form suitable for oral delivery. 158.-. (canceled)59. A gastro-retentive agent delivery device for oral intake , the device configured for unfolding from a folded configuration for oral intake to an unfolded configuration for gastric retention , the device comprising:two external layers sandwiching a functional layer therebetween;the functional layer comprising at least one layer comprising an agent or agent-releasing formulation;the functional layer being configured for imparting mechanical strength to the device sufficient to enable, upon unfolding of the device, the preservation of said unfolded configuration to provide gastric retention;at least one said external layer comprising perforations.60. The device according to claim 59 , wherein in the folded configuration the device has a plurality of folds and a device axis claim 59 , said folds being of increasingly smaller amplitudes upon extending away from the device axis so as to form a partially rounded cross section.61. The device according to claim 59 , wherein said perforations are provided on both said external layers.62. The device according to claim 59 , wherein said external layers are degradable in the intestine.63. The device according to claim 59 , wherein said perforations are produced after said external layers and said functional layer are assembled to form said device.64. The device according to claim 59 , wherein said perforations are produced on the respective said outer layer prior to assembly of said external layers and said functional layer to form said device.65. ...

Подробнее
08-08-2013 дата публикации

MEDICAMENT ADMIXING SYSTEM

Номер: US20130204221A1
Принадлежит: HOSPIRA, INC.

A system for mixing the contents of a first container with the contents of a second container. The second container has a port assembly for receiving the first container. The port assembly has an actuator that is constructed to access the cavity of the first container during activation of the system and to allow fluid communication between the first container and the second container. The port assembly further includes a movable plug that provides a seal for the second container. The plug is configured to move axially relative to the actuator during activation of the system, thereby opening the seal of the second container and providing fluid communication between the first container and the second container. 1. A system for mixing contents of a first container with contents of a second container , the system comprising:a first container defining a cavity and an opening thereto;a stopper positioned within the opening defined by the first container to seal the first container;a second container defining a cavity; anda port assembly attached to the second container, wherein the port assembly is configured to receive the first container, and wherein the port assembly comprises (i) an actuator constructed to access the cavity defined by the first container during activation of the system and to allow fluid communication between the first container and the second container, and (ii) a moveable plug providing a seal for the second container, wherein the moveable plug is configured to move axially relative to the actuator during activation of the system, thereby opening the seal of the second container and providing fluid communication between the first container and the second container.2. The system of claim 1 , wherein the first container comprises a first mating member configured to engage a second mating member of the port assembly.3. The system of claim 2 , wherein the second mating member comprises a retainer claim 2 , and wherein the retainer comprises a plurality ...

Подробнее
08-08-2013 дата публикации

MEDICAMENT ADMIXING SYSTEM

Номер: US20130204222A1
Принадлежит: HOSPIRA, INC.

A medicament container having an opening that provides access to a cavity defined by the medicament container. A stopper is sealingly positioned within the opening of the medicament container and configured to be forced into the cavity to open the medicament container. The medicament container also includes a mating member configured to mate with a complementary receiver associated with a second container to connect the medicament container to a second container. The medicament container further includes a radial seal configured to engage and seal against an interior seal wall associated with a second container prior to the stopper being forced into the cavity defined by the medicament container. A system is also provided for establishing fluid communication between a first container and a second container. The system includes a first container (e.g., a medicament container) having a radial seal, a second container, and a port assembly. 1. A medicament container comprising:an opening providing access to a cavity defined by the medicament container;a stopper sealingly positioned within the opening, wherein the stopper is configured to be forced into the cavity to open the medicament container;a mating member configured to mate with a complementary receiver associated with a second container to connect the medicament container to a second container; anda radial seal configured to engage and seal against an interior seal wall associated with a second container prior to the stopper being forced into the cavity defined by the medicament container.2. The medicament container of claim 1 , wherein the radial seal is configured to engage and seal against an interior seal wall associated with a second container when the medicament container is connected to a second container.3. The medicament container of claim 1 , wherein the radial seal comprises a radially extending annular flange.4. The medicament container of claim 1 , wherein the radial seal is located above the opening ...

Подробнее
22-08-2013 дата публикации

SEXUAL ENHANCEMENT PREPARATIONS AND DEVICES

Номер: US20130217961A1
Автор: Godden Glenn
Принадлежит: EMPIRE TECHNOLOGY DEVELOPMENT LLC

Preparations for sexual enhancement may comprise a lubricant material along with one or more gel battery device. The gel battery devices may be fabricated from a gel anode material and a gel cathode material. The gel batteries may further comprise a gel electrolyte material. The gel materials may be in the form of thin films or capsules. The gel batteries, their anode, cathode, and electrolyte materials may all be non-toxic for an application to an animal. One or more devices for sexual enhancement may be contacted with the sexual enhancement preparation. The preparations or the devices with the preparations may be applied to one or more tissues of an animal. 1. A preparation comprising:a personal lubricant; andat least one gel electrochemical device, whereinthe personal lubricant and the gel electrochemical device are non-toxic for an application to an animal.2. The preparation of claim 1 , wherein the animal is a human.3. The preparation of claim 1 , wherein the personal lubricant is one or more of: a paste claim 1 , a gel claim 1 , and a lotion.4. The preparation of claim 1 , wherein the personal lubricant comprises one or more of: an alcohol claim 1 , an oil claim 1 , a wax claim 1 , a healing agent claim 1 , an odorant claim 1 , a flavorant claim 1 , an emulsifier claim 1 , a protein claim 1 , and a preservative.57.-. (canceled)8. The preparation of claim 1 , wherein the gel electrochemical device comprises:a gel anode;a gel cathode; anda gel electrolyte, whereinat least a portion of the gel anode is in contact with at least a portion of the gel electrolyte, andat least a portion of the gel cathode is in contact with at least a portion of the gel electrolyte.9. The preparation of claim 8 , wherein the gel anode comprises one or more of:zinc metal powder, aluminum metal powder, and magnesium metal powder.1013.-. (canceled)14. The preparation of claim 8 , wherein one or more of the gel anode claim 8 , the gel cathode claim 8 , or the gel electrolyte further ...

Подробнее
19-09-2013 дата публикации

COMPOUND FORMULATIONS

Номер: US20130243858A1
Автор: Khan Karrar Ahmad
Принадлежит:

Solid dosage forms of methylthioninium chloride (MTC) further comprise at least one diluent suitable for direct compression. The MTC exists in a substantially pure and stable polymorphic form. The solid dosage forms may preferably be prepared by direct compression methods. 1. A pharmaceutical composition in solid dosage form comprising , as active ingredient , MTC , said composition further comprising at least one diluent suitable for direct compression , characterised in that the MTC exists in a substantially pure and stable polymorphic form.2. A composition as claimed in claim 1 , wherein the MTC is in polymorph Form A.3. A composition as claimed in or claim 1 , wherein the amount of MTC in the composition is more than about 10% w/w claim 1 , or more than 20% claim 1 , or more than 30% w/w.4. A composition as claimed in claim 3 , wherein the amount of MTC is less than about 75% w/w claim 3 , or less than 60% or less than 50% w/w.5. A composition as claimed in claim 4 , wherein the amount of MTC in the composition is from about 10% w/w (or 20% or 30%) to about 70% w/w (or 60% or 50%).6. A composition as claimed in any preceding claim claim 4 , which comprises at least 15% w/w claim 4 , at least 20% claim 4 , at least 30% claim 4 , at least 40% or at least 50% w/w of diluent(s).7. A composition as claimed in any preceding claim claim 4 , wherein the diluent(s) are selected from the group consisting of microcrystalline cellulose claim 4 , lactose claim 4 , mannitol claim 4 , calcium salts such as calcium phosphate dibasic claim 4 , calcium sulphate and calcium carbonate claim 4 , and sugars such as lactose claim 4 , sucrose claim 4 , dextrose and maltodextrin.8. A composition as claimed in any preceding claim claim 4 , which further comprises a lubricant.9. A composition as claimed in claim 8 , wherein the lubricant is selected from the group consisting of magnesium stearate claim 8 , calcium stearate claim 8 , sodium stearyl fumarate claim 8 , stearic acid claim 8 , ...

Подробнее
19-09-2013 дата публикации

Accessory Device for Inner Ear Drug Delivery

Номер: US20130245569A1
Принадлежит: MED-EL Elektromedizinische Geraete GmbH

An implantable drug delivery accessory is described. A middle ear guide member has a hollow interior enclosed by a non-permeable outer surface. A proximal end of the middle ear guide member is fixed to the tympanic membrane of an implanted patient. A distal end of the middle ear guide member penetrates through a fluid-tight sealed opening into the inner ear. An inner ear holding member has a proximal end connected to the distal end of the middle ear guide member at the sealed opening and a closed distal end terminating the inner ear holding member some predetermined distance within the cochlea. A hollow interior of the inner ear holding member contains a replaceable drug delivery member which stores a therapeutic drug. A semi-permeable outer surface of the inner ear holding member is connected to a cochlear implant electrode and adapted to release therapeutic drug from the hollow interior into adjacent tissue. The drug delivery member is removable and replaceable via the ear canal of the implanted patient through the proximal end of the middle ear. 1. An implantable drug delivery accessory comprising: a hollow interior,', 'a non-permeable outer surface enclosing the hollow interior,', 'a proximal end fixed to the tympanic membrane of an implanted patient, and', 'a distal end penetrating through a fluid-tight sealed opening into the inner ear; and, 'a middle ear guide member having a proximal end connected to the distal end of the middle ear guide member at the sealed opening,', 'a closed distal end terminating the inner ear holding member some predetermined distance within the cochlea,', 'a hollow interior for containing a replaceable drug delivery member which stores a therapeutic drug,', 'a semi-permeable outer surface connected to a cochlear implant electrode and adapted to release therapeutic drug from the hollow interior into adjacent tissue,, 'an inner ear holding member havingwhereby the drug delivery member is removable and replaceable via the ear canal of ...

Подробнее
26-09-2013 дата публикации

METHOD OF PRODUCING A SOLID PREPARATION

Номер: US20130249140A1
Автор: WATANABE Tomoyuki
Принадлежит:

A method for producing a solid preparation containing a compound represented by the formula (I) below or a pharmacologically acceptable salt thereof, which includes a step wherein a composition containing the compound represented by the formula (I) below or a pharmacologically acceptable salt thereof is mixed, while applying a mechanical stress to the composition. The compound of the formula (I) is as follows: 2. The method according to claim 1 , wherein the mechanical stress is 20 N/mmor larger.3. The method according to claim 1 , wherein the mechanical stress is 40 to 600 N/mm.4. The method according to claim 1 , wherein the mechanical stress is 60 to 400 N/mm.6. The method according to claim 1 , wherein the solid preparation is in the form of a tablet.8. The method according to claim 7 , wherein the circumferential velocity at the end of the stirring blade is 5.0 m/s to 40 m/s.9. The method according to claim 7 , wherein the circumferential velocity at the end of the stirring blade is 5.0 m/s to 20 m/s.11. The method according to claim 7 , wherein the solid preparation is in the form of a tablet. This application is a continuation application of application Ser. No. 13/313,165 filed Dec. 7, 2011, which is a divisional application of application Ser. No. 12/312,970 filed Jun. 2, 2009 (abandoned), which is the United States national phase application under 35 USC 371 of International application PCT/JP2007/073549 filed Dec. 6, 2007. The entire contents of each of application Ser. No. 12/312,970, application Ser. No. 13/313,165 and International application PCT/JP2007/073549 are hereby incorporated by reference herein.The present invention relates to a method for producing a solid preparation containing a compound represented by the following general formula (I):or a pharmacologically acceptable salt thereof, which includes a step in which a composition containing the compound represented by the aforementioned general formula (I) or a pharmacologically acceptable ...

Подробнее
26-09-2013 дата публикации

TAMPER RESISTANT DOSAGE FORMS

Номер: US20130251796A1
Принадлежит: Purdue Pharma L.P.

The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof. 1169-. (canceled)170. A solid oral extended release pharmaceutical dosage form comprising an extended release matrix formulation , the extended release matrix formulation comprising a composition comprising at least:(1) at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000; and(2) at least one active agent selected from opioid analgesics wherein the opioid analgesic is oxycodone hydrochloride and the dosage form comprises from 5 mg to 500 mg of oxycodone hydrochloride; andwherein the composition comprises at least about 80% (by wt) polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000.171. The solid oral extended release pharmaceutical dosage form of claim 170 , wherein the opioid analgesic is oxycodone hydrochloride and the composition comprises more than 5% (by wt) of the oxycodone hydrochloride.172. The solid oral extended release pharmaceutical dosage form of claim 170 , wherein the composition comprises 10 mg oxycodone hydrochloride claim 170 , and at least about 85% (by wt) polyethylene oxide.173. The solid oral extended release pharmaceutical dosage form of claim 170 , wherein the composition comprises 15 mg or 20 mg oxycodone hydrochloride.174. The solid oral extended release pharmaceutical dosage form of claim 170 , wherein the density of the extended release matrix formulation is equal to or less than about 1.20 g/cmor equal to or less than about 1.19 g/cm.175. The solid oral extended release pharmaceutical dosage form of claim 170 , wherein the extended release matrix formulation after having been stored at 25° C. and 60% relative humidity (RH) for at least 1 month provides a dissolution rate claim 170 , when ...

Подробнее
26-09-2013 дата публикации

TAMPER RESISTANT DOSAGE FORMS

Номер: US20130251797A1
Принадлежит: Purdue Pharma L.P.

The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof. 1169-. (canceled)170. A solid oral extended release pharmaceutical dosage form comprising an extended release matrix formulation , the extended release matrix formulation comprising a composition comprising at least: (1) at least one polyethylene oxide having , based on rheological measurements , a molecular weight of at least 800 ,000; and (2) at least one active agent selected from opioid analgesics; and wherein the composition comprises at least about 80% (by wt) polyethylene oxide.171. The solid oral extended release pharmaceutical dosage form of claim 170 , wherein the composition comprises at least one polyethylene oxide having claim 170 , based on rheological measurements claim 170 , a molecular weight of at least 900 claim 170 ,000.172. The solid oral extended release pharmaceutical dosage form of claim 170 , wherein the density of the extended release matrix formulation is equal to or less than about 1.20 g/cm3 or equal to or less than about 1.19 g/cm3.173. The solid oral extended release pharmaceutical dosage form of claim 170 , wherein the extended release matrix formulation has a cracking force of at least about 120 N claim 170 , at least about 130 N or at least about 140 N and/or a “penetration depth to crack” distance of at least about 1.2 mm claim 170 , about 1.4 mm claim 170 , about 1.5 mm claim 170 , or about 1.6 mm.174. The solid oral extended release pharmaceutical dosage form of claim 170 , wherein the extended release matrix formulation resists a work of at least about 0.06 J without cracking175. The solid oral extended release pharmaceutical dosage form of claim 170 , wherein the extended release matrix formulation after having been stored at 25° C. and 60% relative humidity (RH) for at least 1 month provides a dissolution rate claim 170 , ...

Подробнее
26-09-2013 дата публикации

Implantable fluid management device for the removal of excess fluid

Номер: US20130253409A1
Автор: Daniel R. BURNETT
Принадлежит: Sequana Medical AG

A device for removing fluid from a first bodily cavity and for directing that fluid into a second bodily cavity while avoiding risks of infection and, in one embodiment, excessive dehydration of the first bodily cavity. The device includes an uptake tube having a proximal end in fluid communication with the first bodily cavity and a distal end in fluid communication with a pump, and an outflow tube having a proximal end in fluid communication with the pump and a distal end in fluid communication with the second bodily cavity. The distal end of the uptake tube may be coupled to a reservoir configured to expand upon ingression of fluid into the reservoir and to contract upon removal of fluid due to a negative pressure provided by the pump.

Подробнее
03-10-2013 дата публикации

DEVICE FOR INTRODUCING FILLING MATERIAL INTO CAPSULES

Номер: US20130255833A1
Принадлежит: ROBERT BOSCH GMBH

The present invention relates to a device for introducing filling material () into capsules (), comprising a filling device () for feeding filling material () to the capsules (), a capsule holder () with at least one row of seats () in which the capsules () that are to be filled are arranged, a station arrangement with several stations arranged one after another, wherein the station arrangement comprises at least one filling station () and a synchronously operating drive, and a movement device which, at the capsule-filling station (), executes a relative movement between the filling device () and the capsule holder (), wherein the filling device () adopts, relative to the capsule holder (), at least a first filling position for filling a first capsule and a second filling position for filling a second capsule. 12122. A device for introducing filling material () into capsules () , said device including:{'b': 25', '21', '22, 'a filling device () for supplying filling material () to the capsules (),'}{'b': 30', '31', '22, 'a capsule holder () with at least one row of accommodating means () in which the capsules () to be filled are arranged,'}{'b': '5', 'a station arrangement having several stations which are arranged one after the other, wherein the station arrangement includes at least one filling station () and one drive which operates in a fixed cycle and'}{'b': 50', '60', '70', '25', '30', '5, 'a movement apparatus (; ; ) which carries out a relative movement between the filling device () and the capsule holder () at the capsule filling station (),'}{'b': 25', '30, 'wherein the filling device (), in relation to the capsule holder (), assumes at least one first filling position for filling a first capsule and one second filling position for filling a second capsule.'}240305060702530. The device as claimed in claim 1 , characterized in that the station arrangement includes a station wheel () with a plurality of capsule holders () and the movement apparatus (; ; ) ...

Подробнее
03-10-2013 дата публикации

CAPACITIVE FLUID LEVEL SENSING

Номер: US20130261539A1
Автор: King David A.
Принадлежит:

A capacitive fluid level sensing arrangement for use in a medical device is provided. The arrangement includes at least one pair of conductive plates configured to increase and decrease the amount of electric charge stored in relation to the level of fluid within a fluid maintaining device, such as a reservoir. The conductive plates are electrically connected to a medical device and are configured to measure the charge stored between the plates and thus sense the fluid level. The electric circuit may communicate the measurement to an instrument host arrangement for operating a pump configured to remove fluid from the reservoir and move the fluid to a collector when the level exceeds a preset upper level amount. The instrument host arrangement may stop operating the pump when the fluid level is reduced to a preset lower level amount. 132-. (canceled)33. A method for performing a surgical procedure , comprising:capacitively sensing fluid level within a medical device configured to be employed to perform the surgical procedure; anddepending on fluid level sensed by said capacitively sensing, selectively altering fluid amount within the medical device by selectively evacuating fluid and selectively adding fluid based on the capacitively sensing.34. The method of claim 33 , wherein the medical device is an ophthalmic surgical device.35. The method of claim 34 , wherein the ophthalmic surgical device is a phacoemulsification system. 1. Field of the InventionThe present invention relates generally to the field of ocular surgery, and more specifically to managing fluid levels within a reservoir using a capacitive sensor device for measuring the reservoir fluid level during ophthalmic procedures such as the removal of a cataract.2. Description of the Related ArtPhacoemulsification surgery has been successfully employed in the treatment of certain ocular problems, such as cataract surgery, including removal of a cataract-damaged lens and implanting an artificial intraocular ...

Подробнее
03-10-2013 дата публикации

IMPROVED METHOD OF TREATING PLEURAL EFFUSION

Номер: US20130261598A1
Принадлежит: CAREFUSION 2200, INC.

The present invention provides methods of treating pleural effusion in a subject, comprising removing fluid from the pleural space at an increased frequency, as compared to previous methods. 1. A method of treating pleural effusion in a subject , comprising:administering two or more treatments comprising removing an amount of fluid from the pleural space of the subject,wherein the treatments are administered at a frequency of every about 12 to about 48 hours until 2 or more consecutive treatments each remove less than 300 mL of fluid.2. The method of claim 1 , wherein the treatments are administered at a frequency of every about 12 to about 36 hours.3. The method of claim 1 , wherein the treatments are administered at a frequently of about every 24 hours.4. The method of claim 1 , wherein the treatments are administered at a frequency of about every about 12 to about 72 hours until 3 or more consecutive treatments each remove less than 300 mL of fluid.5. The method of claim 1 , wherein the treatments are administered at a frequency of about every about 12 to about 72 hours until 2 or more consecutive treatments each remove less than 250 mL of fluid.6. The method of claim 1 , wherein the treatments are administered at a frequency of about every about 12 to about 72 hours until 2 or more consecutive treatments each remove less than 100 mL of fluid.7. The method of claim 1 , wherein the treatments are administered at a frequency of about every about 12 to about 72 hours until 2 or more consecutive treatments each remove less than 50 mL of fluid.8. The method of claim 1 , wherein the amount of fluid removed from the pleural space in a treatment does not exceed 1.5 liters.9. The method of claim 1 , wherein the amount of fluid removed from the pleural space in a treatment does not exceed 1 liter.10. The method of claim 1 , wherein after 2 or more consecutive treatments each remove under 500 mL of fluid claim 1 , the method further comprises one or more treatments at a ...

Подробнее
17-10-2013 дата публикации

SYSTEM AND METHOD FOR IMPROVING OUTCOME OF CEREBRAL ISCHEMIA

Номер: US20130269692A1
Принадлежит:

A system for improving outcome following cerebral ischemia is provided. The system includes a source of nitric oxide and an elongate tubular member for insertion into a nose including at least one orifice thereon. The tubular member is coupled to the source of nitric oxide and the elongate tubular member configured for delivering the nitric oxide into a nasal cavity through the at least one orifice for absorption into a cerebral vasculature through a nasal vasculature. A means for controlling flow of the gas, a concentration of the nitric oxide in the gas, or both, is also provided. 1. A system for improving outcome following cerebral ischemia comprising:a source of a gas comprising NO;an elongate tubular member for insertion into a nose including at least one orifice thereon said tubular member operably coupled to said source of a gas, the elongate tubular member configured for delivering said NO into a nasal cavity through said at least one orifice for absorption into a cerebral vasculature through a nasal vasculature; anda means for controlling flow of the gas, a concentration of the NO in said gas, or both, wherein said outcome following cerebral ischemia is improved.2. The system of wherein said elongate tubular member configured for delivering NO into the nasal cavity is configured to deliver said NO solely into the nasal cavity.3. The system of further comprising an occlusive member positioned within the nasal cavity distal to said at least one orifice for preventing the inhalation of NO into the lungs.4. The system of wherein said occlusive member is configured to prevent the inhalation of NO into the lungs thereby preventing pulmonary vasodilatation.5. The system of wherein said cerebral ischemia is caused by stroke claim 1 , TIA claim 1 , traumatic brain injury claim 1 , cardiac arrest claim 1 , seizure claim 1 , complicated migraine claim 1 , shock claim 1 , vasospasm and combinations of the foregoing.6. The system of wherein said elongate tubular member ...

Подробнее
17-10-2013 дата публикации

IMPLANT DEVICE, TOOL, AND METHODS RELATING TO TREATMENT OF PARANASAL SINUSES

Номер: US20130274647A1
Принадлежит: SINOPSYS SURGICAL, INC.

An implant device is configured to be implanted in a fistula to fluidly connect the lacrimal apparatus and a paranasal sinus. A surgical tool has an implant the implant device mounted on a carrier. Various methods involve a fistula between the lacrimal apparatus and a paranasal sinus. A kit includes an entry device for use to form a fistula and an implant tool for use to implant an implant device following formation of a fistula. 1. An implant device for implantation in a human to fluidly connect a lacrimal apparatus to a paranasal sinus through a fistula formed between the lacrimal apparatus and the paranasal sinus , the implant device comprising:a proximal end at a first longitudinal end of the device;a distal end at a second longitudinal end of the device that is longitudinally opposite the first longitudinal end;a conduit extending from adjacent the proximal end to adjacent the distal end;an internal passage extending between the proximal end and the distal end and through the conduit, the internal passage having a first end open at the proximal end and a second end open at the distal end;a length of the device longitudinally along the device between the proximal end and the distal end in a range of from 2 millimeters to 50 millimeters;a width of the internal passage transverse to the length in a range of from 0.25 millimeter to 5 millimeters; andan exterior of the conduit comprising an anchoring surface feature including protrusion areas and recess areas; the proximal end is disposed with the first end of the internal passage opening in the lacrimal apparatus;', 'the distal end is disposed in the paranasal sinus with the second end of the internal passage opening in the paranasal sinus; and', 'the conduit is disposed through the fistula with at least a portion of the recess areas disposed within the fistula and with at least a portion of the protrusion areas disposed in the fistula and engaging tissue exposed within the fistula to anchor the implant device., ' ...

Подробнее
24-10-2013 дата публикации

BAG FOR LIQUID SOLUTIONS MIXABLE WITH ACTIVE SUBSTANCES AVAILABLE IN A SEPARATE FORM, IN PARTICULAR IN POWDER OR GEL, FOR FORMING LIQUID MEDICINAL OR LIQUID SUBSTANCES THAT ARE ADMINISTRABLE TO PATIENTS THROUGH INTERNAL INSTILLATION

Номер: US20130281923A1
Принадлежит: Ditta Paolo Giuseppe GOBBI FRATTINI

A flexible bag () that is partially filled with a basic liquid solution () has a first end closure () from which a mixing tube () extends that is provided with a frangible closure cap () and a terminal () that is suitable for the connection of a container () of active substance () to be mixed with the basic liquid solution () and a second end closure () from which two dispensing tubes () extend that are provided with respective frangible closure caps (). A first dispensing tube () has a terminal () of the press type and a second dispensing tube () has a terminal () of the screw type (FIG. ). 1. A flexible bag partially filled with a basic liquid solution and having a first end closure from which a mixing tube provided with a frangible closure cap extends , and a terminal suitable for the connection of a container of active substance to be mixed with the basic liquid solution and a second end closure from which two dispensing tubes provided with respective frangible closure extend , a first dispensing tube having a press-fit type terminal and a second dispensing tube having a screw type terminal.2. The flexible bag according to claim 1 , characterized in that said first end closure is provided with holes for the connection of the bag in hanging condition.3. The flexible bag according to claim 1 , characterized in that each of said dispensing tubes is provided with a respective closure clamp.4. The flexible bag according to claim 1 , characterized in that said mixing tube is provided with a closure clamp. The present invention relates to a bag for liquid solutions that are mixable with active substances available in a separate form, in particular in powder or gel, for forming liquid medicinal or liquid substances that are administrable to patients through internal instillation.In hospital environments, there is often a need to administer to patients, by internal instillation, medicinal and nutritional substances of different kinds that are made available separately, ...

Подробнее
31-10-2013 дата публикации

ABUSE-PROOFED ORAL DOSAGE FORM

Номер: US20130287846A1
Принадлежит:

The present invention relates to an abuse-proofed oral dosage form with controlled release of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol for once daily administration, which comprises the active ingredient and/or one or more of the pharmaceutically acceptable salts thereof (A), at least one synthetic or natural polymer (C), delayed-release auxiliary substances, optionally physiologically acceptable auxiliary substances (B) and optionally a wax (D), component (C) or (D) in each case exhibiting a breaking strength of at least 500 N, preferably of at least 1000 N. 1. An abuse-proofed , oral dosage form with controlled release of (1R ,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol for once daily administration , comprising (1R ,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and/or at least one of the pharmaceutically acceptable salts or derivatives thereof (A) , at least one synthetic or natural polymer (C) , optionally delayed-release matrix auxiliary substances , optionally physiologically acceptable auxiliary substances (B) , optionally a wax (D) and optionally at least one delayed-release coating , component (C) or (D) in each case exhibiting a breaking strength of at least 500 N.2. A dosage form according to claim 1 , which is in the form of a tablet.3. A dosage form according to claim 1 , which is in multiparticulate form claim 1 , optionally press-molded into tablets or packaged in capsules.4. A dosage form according to claim 1 , wherein the polymer (C) is at least one polymer selected from among the group consisting of polyethylene oxides claim 1 , polyethylenes claim 1 , polypropylenes claim 1 , polyvinyl chlorides claim 1 , polycarbonates claim 1 , polystyrenes claim 1 , polyacrylates and the copolymers thereof.5. A dosage form according to claim 4 , wherein the polyethylene oxide is of high molecular weight.6. A dosage form according to claim 4 , wherein the polymer (C) is a water-soluble or water-swellable polymer.7. A dosage ...

Подробнее
07-11-2013 дата публикации

Manufacturing and Packaging Room Temperature Stable Dronabinol Capsules

Номер: US20130296415A1
Принадлежит: Insys Therapeutics, Inc.

The invention provides a method of manufacturing and packaging a room temperature stable cannabinoid dosage in an oil-based carrier, wherein the method employs the use of blister packaging and an inert gas atmosphere during blister packaging. The invention also provides a room temperature stable cannabinoid dosage prepared by the methods of the invention. 1. A method of manufacturing and packaging a cannabinoid dosage , said method comprising packaging said dosage in a closed packaging system to provide a room temperature stable product.2. The method of claim 1 , said method comprising the following steps:a) preparing a fill solution with a desired concentration of a cannabinoid in a liquid carrier;b) encapsulating said fill solution in capsules; andc) packaging said capsules in a closed packaging system.3. The method of claim 2 , wherein the packaging step comprises continuously purging said packaging system with an inert gas.4. The method of claim 2 , wherein the packaging system is a blister package.5. The method of wherein the blister package is constructed of material that minimizes exposure to moisture and air.6. The method of claim 2 , wherein the cannabinoid is dronabinol.7. The method of claim 2 , wherein the liquid carrier is oil-based carrier.8. The method of claim 7 , wherein the oil-based carrier is sesame oil.9. The method of claim 8 , further comprising an antioxidant or a stabilizer.10. The method of claim 2 , wherein the capsules are soft gelatin capsules.11. The method of claim 3 , wherein the inert gas is nitrogen.12. The method of claim 2 , wherein the desired cannabinoid concentration is about 1-10% w/w.13. The method of wherein the desired concentration is about 1.5-6.5% w/w14. A method of manufacturing and packaging a cannabinoid dosage claim 11 , said method comprising the following steps: i) heating an oil-based carrier in a first container to 40° C. and above under normal atmospheric conditions or vacuum or an inert gas;', 'ii) heating a ...

Подробнее
14-11-2013 дата публикации

RESPIRATION MEASUREMENTS AND DOSIMETRY CONTROL IN INHALATION TESTING SYSTEMS

Номер: US20130303931A1
Принадлежит:

Inhalation measurement systems and methods enable, during inhalant exposure, substantially real-time respiratory measurements of a test subject using techniques that obtain measurements of respiration directly from that test subject, instead of from inhalation chamber parameter measurements. Direct test subject respiratory measurements may be, by way of example only, impedance measurements. These respiratory measurements taken directly from the test subject may be transmitted, wirelessly for example, for processing during the course of the test to a processing system to determine a cumulative volume of inhalant inspired by the test subject. From that, a cumulative amount of inhalant (or dose) inspired by the test subject may be determined during the course of the inhalation compound test. In addition, a calibration procedure may be performed before the inhalant exposure to provide correlation needed to translate chest and/or abdominal wall expansion measurements, made during the test, into lung volume measurements. 121-. (canceled)22. A method of performing an inhalation test on a subject during which inhalation test the test subject is at least partially confined within a test chamber and an inhalant substance is introduced into the test chamber , the method comprising:collecting during the course of the inhalation test respiration-related measurements for respiration cycles of the test subject using the sensing device applied directly to the test subject; andtiming inhalant concentration changes to a particular phase within a respiratory cycle.23. The method of claim 26 , wherein the respiratory inhalation test further comprises:determining, from the respiratory pattern of the test subject, whether a particle size of the inhalant needs to be modified; andmodifying the inhalant particle size in accordance with the determination.24. The method of claim 22 , wherein the respiratory inhalation test further comprises determining claim 22 , from the position in time ...

Подробнее
21-11-2013 дата публикации

BLOOD SUBSTITUTES AND USES THEREOF

Номер: US20130307170A1
Принадлежит: The General Hospital Corporation

The invention relates to blood substitute compositions, and methods of use thereof. Described herein are compositions in which hemoglobin is maintained substantially in the reduced form of hemoglobin as opposed to the oxidized methemoglobin form through inclusion of an oxido-reductase enzyme and reducing agent within a vesicle with the hemoglobin. The vesicles additionally can comprise a dismutase, a catalase, and an electron acceptor, each of which contribute to either the maintenance of hemoglobin in the active oxygen carrying state or provide a benefit not achieved with free hemoglobin. 124.-. (canceled)25. A method of encapsulating a blood substitute composition , the method comprising the steps of:a. mixing a lipid preparation with a composition comprising an oxido-reductase enzyme, a dismutase, a catalase, a reducing agent, and an electron acceptor;b. extruding the mixture to form lipid vesicles; andc. isolating lipid vesicles.26. The method of claim 25 , wherein the oxido-reductase enzyme comprises DT-diaphorase.27. The method of claim 25 , wherein the dismutase comprises superoxide dismutase.28. The method of claim 25 , wherein the reducing agent comprises NADH or NADPH.29. The method of claim 25 , wherein the electron acceptor comprises methylene blue.30. The method of claim 25 , wherein the lipid preparation comprises at least one lipid selected from the group consisting of: DPPC claim 25 , DSPC claim 25 , DOPC claim 25 , DLPC claim 25 , DPPG claim 25 , DSPG claim 25 , DHPG claim 25 , DOPG claim 25 , DSPEG PEG 5000 claim 25 , DSPE-PEG200 claim 25 , and DOPE-PEG5000.31. The method of claim 30 , wherein the lipid preparation comprises:a. at least one lipid selected from the group consisting of: DPPC, DSPC, DOPC, and DLPC;b. at least one lipid selected from the group consisting of: DPPG, DSPG, DHPG, and DOPG; andc. at least one lipid selected from the group consisting of: DSPEG PEG 5000, DSPE-PEG200, and DOPE-PEG5000.32. The method of claim 25 , wherein the ...

Подробнее
28-11-2013 дата публикации

SELF-VENTING CANNULA ASSEMBLY

Номер: US20130317472A1
Автор: Finke Melvin A.
Принадлежит: COVIDIEN LP

The present disclosure relates to a self-venting cannula assembly. The self-venting cannula assembly including an outer tube that defines a throughbore, an inner tube, a vent aperture, and a filter element. The inner tube is positioned within the outer tube, which defines a vent channel therebetween. The vent aperture is formed in the outer tube to provide fluid communication between the vent channel and an external environment. The filter element is positioned over the vent aperture and prevents particles having a dimension greater than about 0.2 microns from passing therethrough. 112-. (canceled)13. A self-venting cannula assembly comprising:an outer tube defining a longitudinal axis and having an outer surface and an inner surface;an inner tube positioned within the outer tube, the inner tube and the inner surface of the outer tube defining a vent channel;a vent aperture formed in the outer tube to provide fluid communication between the vent channel and an external environment; anda filter element positioned on the outer surface of the outer tube and over the vent aperture, the filter element being configured to prevent particles having a dimension greater than about 0.2 microns from passing through the filter element.14. The self-venting cannula assembly according to claim 13 , wherein an inner diameter of the outer tube is larger than an outer diameter of the inner tube such that the vent channel is annular.15. The self-venting cannula assembly according to claim 13 , further including a hub portion having a proximal portion with an open proximal end and a distal portion claim 13 , the distal portion secured to a proximal end of the outer tube claim 13 , the hub portion being adapted to engage a medical injection device.16. The self-venting cannula assembly according to claim 15 , wherein the open proximal end of hub portion includes a luer-type connector.17. The self-venting cannula assembly according to claim 15 , wherein the outer tube and the hub portion ...

Подробнее
05-12-2013 дата публикации

PROCESS FOR THE PRODUCTION OF AN ABUSE-PROOFED DOSAGE FORM

Номер: US20130320592A1
Принадлежит:

The present invention relates to a process for the production of abuse-proofed, thermoformed dosage forms containing, apart from one or more active ingredients with potential for abuse and optionally physiologically acceptable auxiliary substances, at least one synthetic or natural polymer with a breaking strength of at least 500 N. 1. A process for the production of a solid pharmaceutical dosage forms with at least reduced potential for abuse , comprising:a) shaping a formulation mixture into formed articles by application of force, the formulation mixture comprising at least one active ingredient with potential for abuse, at least one synthetic or natural polymer (C), which exhibits a breaking strength of at least 500 N, and optionally auxiliary substances (B);b) optionally singulating and optionally in each case grading the formed articles by size and,c) after or during heating at least to the softening point of the polymer (C), exposing the formed articles to force until they have a breaking hardness of at least 500 N, and optionally providing them with a cover and optionally mixing all the formed articles back together again.2. A process according to claim 1 , which is performed continuously or discontinuously.3. A process according to claim 1 , wherein the formulation mixture consists to an extent of at least 30 wt. % of component (C).4. A process according to claim 1 , wherein the formulation mixture consists to an extent of at least 50 wt. % of component (C).5. A process according to claim 1 , wherein a) shaping of the formulation mixture proceeds with application of a force of at least 0.5 kN and optionally with heating to less than 60° C.6. A process according to claim 1 , wherein claim 1 , according to c) claim 1 , the formed articles are heated to at least 60° C. before or during application of force of at least 0.1 kN.7. A process according to claim 1 , wherein the application of force according to a) or c) is performed with the assistance of a press ...

Подробнее
12-12-2013 дата публикации

METHODS OF DELIVERING STABLE TOPICAL DRUG COMPOSITIONS

Номер: US20130330381A1
Принадлежит: Transdermal Biotechnology, Inc.

A method of delivering a drug composition comprises providing a carrier having a phosphatidylcholine component and a drug entrapped therein, and applying the composition to the skin for transdermal delivery of the drug, wherein the composition is stable at room temperature. 119-. (canceled)20. A method of formulating a topical transdermal polypeptide composition comprising:providing a polyglycol or a mixture of polyglycols;adding polyenylphosphatidylcholine-enriched phosphatidylcholine into the polyglycol to form a phosphatidylcholine solution;mixing the phosphatidylcholine solution until the phosphatidylcholine solution is clear;warming the phosphatidylcholine solution to form a warmed solution;combining siloxylated polyether and polydimethylsiloxane to form a fluid;adding the fluid to the warmed solution and mixing until the solution is clear;adding methyl paraben to the solution and mixing until the methyl paraben dissolves in the solution;adding warmed water to the solution;cooling the solution to room temperature to form a multilamellar liquid crystal carrier; andmixing a polypeptide solution into the multilamellar liquid crystal carrier to entrap the polypeptide solution within the carrier.21. A method of formulating a topical transdermal polypeptide composition , the method comprising:adding polyenylphosphatidylcholine-enriched phosphatidylcholine to at least one polyglycol to form a phosphatidylcholine solution;adding siloxylated polyether, polydimethylsiloxane, and methyl paraben to the phosphatidylcholine solution; andwarming and cooling the phosphatidylcholine solution to form a non-liposomal multilamellar liquid crystal carrier.22. The method of claim 21 , the method further comprising adding a polypeptide solution to the carrier.23. The method of claim 22 , wherein the polypeptide solution comprises oxytocin claim 22 , vasopressin claim 22 , insulin claim 22 , somatotropin claim 22 , calcitonin claim 22 , chorionic gonadotropin claim 22 , menotropins ...

Подробнее
12-12-2013 дата публикации

METHODS FOR TREATING HEADACHES

Номер: US20130331769A1
Принадлежит: Capnia, Inc.

Apparatus, methods, and kits for treating symptoms associated with common ailments, such as headaches, rhinitis, asthma, epilepsy, nervous disorders and the like, are provided. The apparatus comprises dispensers for carbon dioxide and other therapeutic gases. The methods comprise delivering small volumes of these gases to patients in a manner where the gas infuses into a body region in order to bathe the mucous membranes therein. It has been found that even very short exposure of patients to small volumes and high concentrations of such gases can provide significant relief from symptoms. 113-. (canceled)14. A method for treating a rhinitis or conjunctivitis in a patient in need of such treatment , said method comprising:releasing from a hand-held dispenser a therapeutic, non-inhaled, dosage of a gas comprising at least 50% carbon dioxide by volume, wherein the therapeutic dosage of the gas is accomplished at a repeatable flow rate from 1 cc/sec to 20 cc/sec.15. The method of claim 14 , wherein the duration is from 1-100 seconds per nostril.16. The method of claim 14 , wherein the dose is repeated from 1 to 10 times.17. The method of claim 14 , wherein the method is for treating rhinitis and the rhinitis is allergic rhinitis.18. The method of claim 14 , wherein the hand held dispenser is a two-piece dispenser.19. The method of claim 14 , wherein the hand held dispenser is a one-piece dispenser.21. The method of claim 14 , wherein the flow rate is selected by the patient.22. The method of claim 14 , wherein the flow rate is from 4 cc/sec to 5 cc/sec.23. The method of claim 14 , wherein the flow rate is from 1 cc/sec to 5 cc/sec.24. The method of claim 14 , wherein the flow rate is from 2 cc/sec to 10 cc/sec.25. The method of claim 14 , wherein the flow rate is 10 cc/sec.26. The method of claim 14 , wherein the gas comprises at least 50% carbon dioxide.26. The method of claim 14 , wherein the gas comprises at least 70% carbon dioxide.27. The method of claim 14 , ...

Подробнее
12-12-2013 дата публикации

DRUG RELEASING PELVIC TREATMENT SYSTEM AND METHOD

Номер: US20130331818A1
Принадлежит: AMS Research Corporation

Various embodiments of a pelvic treatment system and method are provided. The present invention can include one or more drug eluting darts or barbs that are lodged into the wall and will elute the drug over a desired time period (weeks, months for example) to treat OAB, BPH, tissue weaknesses, or other disorders or diseases. 1. A system for delivering a therapeutic agent to a pelvic tissue comprising:a delivery device configured for insertion through a pelvic passageway in a patient;the device comprising a distal end comprising an expandable elastic portion having a tissue-contacting surface configured to come in contact with pelvic tissue;tissue penetrating members projecting from the tissue-contacting surface of the expandable elastic portion, the tissue penetrating member configured for detachment from the expandable elastic portion after the members have penetrated the pelvic tissue; anda therapeutic agent releasable from the tissue penetrating member.2. The system of claim 1 , wherein the delivery device is configured for insertion through the urethra claim 1 , the vagina claim 1 , or the uterus.3. The system of claim 1 , wherein the expandable elastic portion having a tissue-contacting surface configured to come in contact with the inner surface of the bladder wall claim 1 , the inner surface of the vaginal wall claim 1 , or the inner surface of the uterine wall.4. The system of wherein the expandable elastic portion comprises an inflatable balloon.5. The system of wherein the tissue penetrating member has an elongate shape and comprises proximal and distal ends.6. The system of wherein the tissue penetrating member has a length from it proximal to distal end in the range of about 50 μm to about 2000 μm claim 5 , or about 100 ηm to about 1500 μm claim 5 , or about 200 μm to about 1000 μm claim 5 , or about 250 μm to about 750 μm.7. The system of wherein the tissue penetrating member has an average diameter in the range of about 15 μm to about 1000 μm claim 5 , ...

Подробнее
02-01-2014 дата публикации

METHOD FOR PREPARING STABLE-TYPE VITAMIN A MICROCAPSULES CONTINUOUSLY

Номер: US20140001662A1
Принадлежит: ZHEJIANG NHU COMPANY LTD

A method for continuously preparing stable-type vitamin A microcapsules is disclosed. The method comprises the following steps: adding vitamin A crystals and an antioxidant into a crystal melter continuously according to a certain ratio under the protection of nitrogen to prepare vitamin A melting oil containing the antioxidant; pumping the above melting oil into a high gravity rotary packed bed emulsifier with a liquid distributor by a pump, and pumping aqueous solution containing gellable modified starch into the above high gravity rotary packed bed emulsifier after deoxidation treatment to obtain vitamin A emulsion at the outlet of the high gravity rotary packed bed emulsifier; and atomizing and spraying the emulsion continuously in a cooled starch bed for granulating, and performing fluidization drying and gelation treatment in a fluidized bed by taking nitrogen as a drying medium to obtain the stable-type vitamin A microcapsules. Above method has the advantage of capability of continuous production, and has good embedding effect due to adopting the gellable modified starch, granulating and gelation treatment, thus the product has good storage stability. 1. A method for continuously preparing stabilized vitamin A microcapsules , characterized in that the method comprises the following steps:1) under the protection of nitrogen gas, continuously adding vitamin A crystals and an antioxidant in a weight ratio of 100:1˜5 into a crystal melter, melting at 65˜75° C., to form vitamin A melting oil containing the antioxidant;2) dissolving gellable modified starch in water at 65˜75° C., to form aqueous solution of 30˜40% modified starch, and deoxygenating at a vacuum of −0.07˜−0.08 MPa for 1˜2 hours;3) pumping the vitamin A melting oil into a high gravity rotary packed bed emulsifier equipped with a liquid distributor; meanwhile, pumping the deoxygenated aqueous solution of modified starch into the same high gravity rotary packed bed emulsifier, to obtain a vitamin A ...

Подробнее
09-01-2014 дата публикации

TABLET PRESS

Номер: US20140007784A1
Автор: Gamlen Michael
Принадлежит:

The invention concerns a tablet press () which is typically portable and comprises a base () and a press member () held relative to the base by a spacer (). The base () comprises a die (B) for receiving a powder in use, wherein the spacer () depends from the base and is moveable relative thereto under the control of an actuator () such that the press member () is reversibly actuable between an at-rest condition in which the press member is spaced from the die and an actuated condition in which the press member is located in the die so as to apply a load to a powder therein so as to compact the powder into a tablet. The actuator is operated under the control of an electronic controller, typically in response to desired tablet parameters input by a user. A table-top tablet press of this kind is particularly beneficial for individual or small-batch tablet production, for example for research purposes. 1. A tablet press comprising:a base;a press member held relative to the base by a spacer, the base comprising a die for receiving a powder in use, wherein the spacer depends from the base and is moveable relative thereto under the control of an actuator such that the press member is reversibly actuable between an at-rest condition in which the press member is spaced from the die and an actuated condition in which the press member is located in the die and applies a load to a powder therein; andan electronic controller for controlling operation of the actuator.2. A tablet press according to claim 1 , wherein the tablet press is portable.3. A tablet press according to claim 1 , wherein the actuator comprises an electric motor.4. A tablet press according to wherein the controller is arranged for digital control of the actuator.5. A tablet press according to claim 1 , wherein the controller controls the actuator to undergo a single pressing cycle in response to a user input.6. A tablet press according to claim 5 , wherein the pressing cycle comprises a first actuation of the ...

Подробнее
23-01-2014 дата публикации

DOUBLE-ENDED NEEDLE AND MIXING INSTRUMENT

Номер: US20140021076A1
Принадлежит: TERUMO KABUSHIKI KAISHA

A double-ended needle and a mixing instrument which are capable of suppressing a reverse flow of a solution are provided. A double-ended needle which constitutes part of a mixing instrument includes a first puncture portion and a second puncture portion having inner cavities thereof communicating with each other, an inner cavity of the first puncture portion and an inner cavity of the second puncture portion communicate with each other, and the lateral cross-sectional area of the inner cavity of the first puncture portion is smaller than the lateral cross-sectional area of the inner cavity of the second puncture portion. 1. A double-ended needle used in a mixing instrument configured to mix a first component and a liquid second component , comprising:a first puncture portion capable of sticking into a first container in which the first component is contained; anda second puncture portion capable of sticking into a second container in which the second component is contained;wherein an inner cavity of the first puncture portion and an inner cavity of the second puncture portion are in communication with each other, and the lateral cross-sectional area of the inner cavity of the first puncture portion is smaller than the lateral cross-sectional area of the inner cavity of the second puncture portion.2. The double-ended needle according to claim 1 , whereinan inner cavity of the double-ended needle is reduced gradually from the second puncture portion to the first puncture portion.3122. The double-ended needle according to claim 1 , wherein the ratio (d/d) between an inner diameter dl of a thinnest portion of the inner cavity of the first puncture portion and an inner diameter d of a thickest portion of the inner cavity of the second puncture portion is 0.25 to 0.85.4122. The double-ended needle according to claim 1 , wherein a ratio (d/d) between the inner diameter dl of a thinnest portion of the inner cavity of the first puncture portion and the inner diameter d of a ...

Подробнее
23-01-2014 дата публикации

LAMINATED TABLET AND MANUFACTURING METHOD THEREFOR

Номер: US20140023708A1
Принадлежит: Takeda Pharmaceutical Company Limited

According to the present invention, a multilayer tablet showing suppressed layer separation and a production method thereof are provided. A concave portion having a depth of not less than 0.1 mm Ka is formed on at least one surface Sa of the both front and back surfaces (Sa, Sb) of a multilayer tablet. Particularly, a multilayer structure obtained by, in tableting, forming a convex portion for forming the concave portion on at least the upper punch, and preliminarily compressing all layers in the multilayer tablet with the upper punch to form a concave portion having the same shape with a depth of not less than 0.1 mm on the upper surface of all layers, wherein the powder materials of the next layer are protruding into the concave portion, is a preferable embodiment. 1. A multilayer tablet comprising a concave portion having a depth of not less than 0.1 mm formed on at least one surface of both the front and back surfaces of the multilayer tablet.2. The multilayer tablet according to claim 1 , wherein a layer having said one surface having the concave portion is the top layer claim 1 ,each of all layers other than the top layer has a concave portion with the same shape as said concave portion, in a top layer-side surface of the both surfaces of each layer, and the materials of the next layer are protruding into the concave portion.3. The multilayer tablet according to claim 1 , wherein said concave portion is one or more groove-like concave portions.4. The multilayer tablet according to claim 3 , wherein a groove-like concave portion is present along a straight line or a curve passing through the center point of one surface having said concave portion claim 3 , when the surface is viewed straight on.5. The multilayer tablet according to claim 4 , wherein said groove-like concave portion runs from one point on the outer circumference of said one surface claim 4 , passes through the center point of the surface claim 4 , and reaches a point on the opposite side of the ...

Подробнее
23-01-2014 дата публикации

METHODS AND DEVICES FOR DELIVERING TO CONDUIT

Номер: US20140024934A1
Автор: LEE-SEPSICK Kathy
Принадлежит: Femasys, Inc.

The present invention comprises systems, methods and devices for the delivery of compositions for diagnosing or treating conduits. The delivery system is positioned to allow for placement of the composition into the body conduit. Use of delivery systems, methods and devices for delivering to a body conduit are also included. 1. A method for diagnosing and treating at least a portion of one or two conduits in a human or animal body , comprising ,(a) providing a delivery system that delivers an effective amount of one or more compositions, wherein the delivery system comprises a delivery device comprising an introducer shaft comprising one or two exit ports for providing one or two catheters, one or two catheters each comprising an end structure on a delivery end, one or more compositions, and a means for providing the one or more compositions into and through the one or two catheters;(b) delivering an effective amount of a composition comprising a diagnostic material such that the composition enters at least a portion of the one or two conduits; and(c) delivering an effective amount of a composition comprising a therapeutic material such that the composition enters at least a portion of the one or two conduits.2. The method of claim 1 , wherein the one or two conduits is a fallopian tube of a mammal.3. The method of claim 1 , wherein delivering an effective amount of a composition comprising a diagnostic material and delivering an effective amount of a composition comprising a therapeutic material occur without removal and re-introduction or substantial repositioning of the introducer shaft.4. The method of claim 1 , wherein delivering an effective amount of a composition comprising a diagnostic material and delivering an effective amount of a composition comprising a therapeutic material occur sequentially or simultaneously.5. The method of claim 1 , wherein the composition comprising a diagnostic material and the composition comprising a therapeutic material are ...

Подробнее
06-02-2014 дата публикации

Connector Device

Номер: US20140034185A1
Принадлежит: ROCHE DIAGNOSTICS INTERNATIONAL AG

A connector device for connecting two containers with first and second members slidably displaceable in regard to each other along an axis between a first and a second position is presented. The first member comprises a needle parallel to the axis so that the first container's septum is penetrated by one end of the needle when the first container is introduced into the first member. The second member comprises a coupling to the second container. The other needle end penetrates the second container's septum when the members are in the second position establishing a connection between the two containers. The first member comprises a coupling to the second container coupled to the second member. The first member can couple to the second container when the two members are in the second position and cannot couple to the second container when the two members are in the first position. 1. A connector device for fluidly connecting two containers with two members that are slidably displaceable in regard to each other along an axis between a first and a second position , the connector device comprises:a first member comprising a needle with two ends arranged parallel to the axis in such a way that a septum of the first container is penetrated by one end of the needle when the first container is introduced into a receptacle of the first member;a second member comprising a releasably coupling to a second container wherein the other end of the needle does not come into contact with a septum of the second container coupled to the second member when the members are in the first position, and the other needle end penetrates the septum of the second container when the members are in the second position establishing a fluid connection between the two containers; andwherein the first member comprises a releasably coupling to the second container that is coupled to the second member and wherein the coupling of the first member couples to the second container when the two members are in ...

Подробнее
13-02-2014 дата публикации

Pharmaceutical Dosages Delivery System

Номер: US20140046147A1
Принадлежит: PROTEUS DIGITAL HEALTH, INC.

Pharmaceutical delivery systems for delivering dosages according to the present invention include a carrier component and a cap configured to seal an internal volume of the carrier component, wherein the cap includes a device that produces a unique current signature. Dosages prepared to be delivered according to embodiments of the invention find use in a variety of different applications, including clinical trials. 1. A pharmaceutical delivery system for tracking delivery parameters , the system comprising:a carrier housing having a closed end and an open end, wherein the carrier housing defines a cavity;a pharmaceutical agent positioned within the cavity of the carrier housing; anda cap comprising a top end and a bottom end, wherein the bottom end includes a sealing portion that is in physical communication with the open end of the carrier housing to seal the cavity containing the pharmaceutical agent; anda device associated with the system, wherein the device produces an identifiable current signature for communicating information.2. The system of claim 1 , wherein the device is secured to a top portion of the cap such that the device is able to come into contact with the surrounding environment as the carrier housing comes into contact with the surrounding environment.3. The system of claim 1 , wherein the sealing portion defines at least one channel that allows the cap to be pressure fitted into the open end of the carrier housing.4. The system of claim 1 , wherein the device is secured to the bottom end such that the device comes into contact with the surrounding environment after the system is ingested and the cap separates from the carrier housing.5. The system of claim 1 , wherein the sealing portion is secured to the open end of the carrier housing using an adhesive.6. The system of claim 1 , wherein the device comprises:a frame;a conductance control module secured within the frame for producing the identifiable current signature representing the ...

Подробнее
13-02-2014 дата публикации

LOW PROFILE AGENT DELIVERY PERFUSION CATHETER HAVING A FUNNEL-SHAPED MEMBRANE

Номер: US20140046300A1
Принадлежит: Abbott Cardiovascular Systems Inc.

An agent delivery catheter and method configured to deliver an agent to an inner surface of a patient's body lumen wall by forming a funnel shaped agent containment chamber around at least one portion of the inner surface of the body lumen wall, while minimizing ischemic conditions during the procedure. 118-. (canceled)19. A catheter for delivering an agent to an inner surface of a patient's body lumen wall , comprising:a) an elongated shaft having a distal shaft section and an agent delivery lumen which is in fluid communication with an agent delivery distal port in the distal shaft section;b) a frame made from a self-expanding material mounted on the distal shaft section which is biased to expand from a collapsed configuration to an expanded configuration against the patient's body lumen wall, the frame having a loop which remains adjacent to the lumen wall when the frame is in the expanded configuration; andc) an expandable membrane having a mouth secured to the loop of the frame and a base secured to the elongated shaft at the agent delivery distal port so that an inner surface of the membrane defines a chamber in fluid communication with the agent delivery lumen, the mouth of the membrane being movable with the loop when the frame is placed in the expanded configuration such that the mouth of the membrane sealingly engages a portion of the patient's body lumen wall to thereby expose the portion of the wall to agent delivered from the shaft agent delivery lumen and contained within the chamber of the membrane.20. The catheter of claim 19 , wherein the frame in the expanded configuration has at least one perfusion pathway therethrough claim 19 , which is outside of the expanded membrane and shaft claim 19 , and which is configured to allow blood from within the patient's body lumen to flow past the frame from the proximal to the distal end of the frame.21. The catheter of claim 20 , having a second expandable membrane having a mouth secured to a second loop of ...

Подробнее
27-02-2014 дата публикации

Buccal Drug Delivery

Номер: US20140054826A1
Принадлежит: Gelmedic Holding AG

A lozenge is provided that has stable pH and stable levels of active ingredient over time. It comprises a combination of (i) at least one gum and (ii) at least one non-crystallising sugar or non-crystallising sugar alcohol in a matrix designed for controlled buccal delivery of a drug. The lozenge also contains water and optional components selected from flavourings, taste masking agents, colourings, buffer components, pH adjusting agents, excipients, stabilizers and sweeteners. Methods of preparing the lozenge are also provided. 150-. (canceled)52. A method according to claim 51 , wherein the mixture is heated to approximately 110-120° C.53. A method according to comprising the further steps:b1) adding one or more buffering agents; andb2) adding a pH adjustment agent to adjust the pH to approximately 7.5-9.0.54. A method according to claim 51 , comprising the further step of allowing the mixture to rest.55. A method according to claim 51 , wherein step d) comprises the sub-steps of:d1) transferring the mixture to a moulding apparatus; andd2) moulding the mixture to form lozenges.56. A method according to further comprising the step of drying the lozenges.57. A method according to wherein the active agent is added in the form of a micronised powder claim 51 , an ethanolic solution or an aqueous solution.58. A method according to wherein the produced glassy lozenge comprises:a) a matrix having a hydrogel structure;b) an active agent selected from an anti-emetic agent, an agent for migraine treatment, and an analgesic agent;c) water; andd) optionally one or more components selected from flavorings, taste masking agents, colorings, buffering agents, pH adjusting agents, excipients, stabilizers and sweeteners,wherein the matrix comprises (i) at least one gum and (ii) at least one non-crystallising sugar or non-crystallising sugar alcohol; and wherein the lozenge dissolves or disintegrates gradually.59. A method of making a glassy lozenge for buccal delivery comprising a ...

Подробнее
13-03-2014 дата публикации

Applicator for dispensing a medicinal substance

Номер: US20140074051A1
Принадлежит:

Applicators , and include a body with a stem having an axially-formed slot delivery passage . Slot is formed transaxially through stem in communication with slot delivery passage . Proximal and distal transition surfaces and are formed at axial ends of slot . Stem of applicator is tapered axially distally inward. Flat surface may be formed adjacent slot . The body is formed with flange having a seat for receipt of a vagina or anus of a patient. Stem of the applicator is curved away from a normal axis of the body. Stem-like proximal section of the body of applicator is curved away from the normal axis of the body, with a distal end of the section integrally joined with a proximal end of the straight stem 1. An applicator for dispensing a medicinal substance therethrough , where the substance has a cream-like consistency of the type which does not flow without a force being applied thereto , which comprises:a body formed about an axis which extends from a proximal end of the body to an exterior axial surface of a closed distal end of the body;the body formed with a proximal section, a flange, a stem having an external surface, a solid spacer having an outer surface, and a dome, all of which extends from the proximal end of the body to the closed distal end of the body;a slot delivery passage formed axially through the stem;an axially-elongated slot having a proximal end and an axially-spaced distal end formed radially through the stem in unobstructed communication with the slot delivery passage and the external surface of the stem; anda ramp-like transition surface formed axially distally adjacent, and outside of, the distal end of the slot and into an outer surface of the solid spacer.2. The applicator as set forth in claim 1 , where the ramp-like transition surface is a distal ramp-like transition surface claim 1 , which further comprises:a proximal ramp-like transition surface formed axially proximally adjacent, and outside of, the proximal end of the slot and into ...

Подробнее
13-03-2014 дата публикации

DEVICE AND METHOD FOR TREATING THE ANAL SPHINCTER

Номер: US20140074066A1
Автор: Barak Nir
Принадлежит:

A rectally insertable device for localized drug delivery to the anal sphincter of a subject, a method of using the device and the use of the device is disclosed. The device comprises a shell for containing an active pharmaceutical ingredient, the shell being substantially impermeable to the active pharmaceutical ingredient wherein a lower portion of the shell is configured to release the active pharmaceutical ingredient from the shell and wherein when the device is inserted into the rectum of the subject, the lower portion of the shell is proximal to the anal sphincter, such that the active pharmaceutical ingredient is released proximal to the anal sphincter. 130-. (canceled)32. The device of wherein an outer surface of the shell is provided with a lubricant layer.33. The device of wherein the lubricant layer comprises a local anesthetic.34. The device of wherein the shell is provided with a rounded tip.35. The device of wherein the shell is collapsible upon the release of the active pharmaceutical ingredient.36. The device of wherein the carrier further comprises at least one additional active pharmaceutical ingredient.37botulinum. The device of wherein the active pharmaceutical ingredient is selected from the group consisting of a herbal extract claim 31 , bee pollen claim 31 , a muscle relaxant claim 31 , a local anesthetic claim 31 , an antibiotic claim 31 , an anti-inflammatory agent claim 31 , a nitric oxide donor claim 31 , toxin claim 31 , a muscarinic agent claim 31 , a sympathetic neuromodulator claim 31 , a calcium channel antagonist claim 31 , a phosphodiesterase inhibitor claim 31 , a superoxide scavenger claim 31 , a cyclic adenosine monophosphate-dependent protein kinase activator claim 31 , an adenosine triphosphate-sensitive calcium channel activator and mixtures thereof.38. The device of wherein the calcium channel antagonist is nifedipine.39. The device of wherein the carrier is polyethylene glycol.40. The device of wherein the at least one ...

Подробнее
03-04-2014 дата публикации

FEBUXOSTAT COMPOSITIONS

Номер: US20140093563A1
Принадлежит: RANBAXY LABORATORIES LIMITED

The present invention relates to an oral pharmaceutical composition of febuxostat which comprises an intragranular component and an extragranular component. Further, it relates to processes for the preparation of said composition and a method of using said composition. 1. An oral pharmaceutical composition of febuxostat comprising:(A) an intragranular component comprising: (i) an effective amount of febuxostat, (ii) wetting agent(s), (iii) diluent(s), (iv) binder(s), (v) disintegrant(s), and optionally (vi) glidant(s); and(B) an extragranular component comprising: (i) diluent(s), (ii) disintegrant(s), (iii) lubricant(s), and optionally (iv) glidant(s)wherein the intragranular component comprises a wetting agent and a granulating liquid and the wetting agent is added to the granulating liquid.2. The pharmaceutical composition according to claim 1 , wherein the wetting agent is present in an amount of more than 0.5% and less than 3% by weight of the composition.3. The pharmaceutical composition according to claim 1 , wherein febuxostat is present in an amount of from about 2% to about 50% by weight of the composition.4. The pharmaceutical composition according to claim 1 , wherein the median particle size (D) of febuxostat ranges from about 0.1 μm to about 6 μm.5. The pharmaceutical composition according to claim 4 , wherein the median particle size (D) of febuxostat ranges from about 1 μm to about 4 μm.6. The pharmaceutical composition according to claim 1 , wherein a portion of the binder is blended with the drug and the remaining portion is added to the granulating liquid.7. The pharmaceutical composition according to claim 1 , wherein the ratio of binder in the dry mix portion to that in the granulating liquid portion ranges from about 1:10 to about 10:1.8. The pharmaceutical composition according to claim 1 , wherein the disintegrant is present an amount of from about 5% to about 10% by weight of the composition.9. The pharmaceutical composition according to ...

Подробнее
10-04-2014 дата публикации

CAPSULES COMPRISING AN EMULSIFIED SYRUP AND METHODS OF MAKING THE SAME

Номер: US20140099363A1
Автор: LIN JING
Принадлежит: R.P. SCHERER TECHNOLOGIES, LLC

This invention provides capsules and, more specifically soft capsules, wherein the fill material comprises an emulsified syrup. In particular, the present invention provides a means of encapsulating honey in a gelatin, modified-gelatin or gelatin-free shell material. Furthermore, the capsules described herein are capable of being manufactured using a rotary die apparatus. 1. A capsule for a complementary health or pharmaceutical product comprising:(a) a hard or soft shell for encapsulating a fill material; and(b) a fill material comprising at least one emulsified syrup.2. A capsule according to claim 1 , wherein the emulsified syrup comprises at least one syrup claim 1 , at least one emulsifier and at least one oil or oil mixture claim 1 , and optionally water.3. A capsule according to claim 2 , wherein the at least one syrup is selected from the group consisting of honey claim 2 , maple syrup claim 2 , molasses claim 2 , sugar cane syrup and malt extract.4. A capsule according claim 3 , wherein the honey is liquid honey claim 3 , creamed honey or crystallized honey.5. A capsule according to claim 2 , wherein the emulsifier comprises at least one ionic or non-ionic edible surfactant claim 2 , preferably selected from the group comprising lecithin claim 2 , polyoxyethylene fatty acid esters claim 2 , glycerides of fatty acids claim 2 , polyoxyethylene castor oil derivatives and sorbitan esters.6. A capsule according to claim 2 , wherein the oil or oil mixture comprises at least one medium or long chain mono- claim 2 , di- or tri-glyceride claim 2 , preferably selected from the group consisting of medium chain triglycerides claim 2 , soya oil claim 2 , sunflower oil claim 2 , safflower oil and rice bran oil.7. A capsule according to claim 1 , wherein the total water content of the fill material is less than 12.5% wt/wt.8. A capsule according to claim 1 , wherein the fill material further comprises one or more complementary health or pharmaceutically active compounds.9 ...

Подробнее
06-01-2022 дата публикации

MICRO-ROBOT OPERATING DEVICE USING UNIDIRECTIONAL ULTRASONIC TRANSDUCER, AND SYSTEM USING SAME

Номер: US20220001157A1
Принадлежит:

A micro-robot operating system using an ultrasonic transducer according to an embodiment of the present invention may comprise: a micro-robot moving in an inspection object; and a micro-robot operating device for controlling the location of the micro-robot. A micro-robot operating device using an ultrasonic transducer may comprise: an ultrasonic transducer unit including a plurality of ultrasonic transducers; and a control unit for controlling the plurality of ultrasonic transducers, wherein the plurality of ultrasonic transducers are arranged to form a curved surface toward a particular location in a space. 1. A microrobot driving apparatus using ultrasonic transducers , comprising:an ultrasonic transducer unit comprising a plurality of ultrasonic transducers; anda control unit controlling the plurality of ultrasonic transducers,wherein the plurality of ultrasonic transducers is arranged to form a curved surface in a way to be directed toward a specific location in a space,the control unit applies a signal to each ultrasonic transducer, included in the plurality of ultrasonic transducers, with a time delay in order to change a location of a focus, andthe focus indicates a vertical height where microrobots are disposed with respect to the ultrasonic transducer unit.2. The microrobot driving apparatus of claim 1 , further comprising:a motor stage unit for adjusting a location on a plane identical with a plane of the ultrasonic transducer unit,wherein the control unit controls the motor stage unit.3. The microrobot driving apparatus of claim 2 , further comprising:an interface comprising a liquid medium,wherein the interface is disposed between the microrobot driving apparatus and a space where the microrobots are disposed.4. The microrobot driving apparatus of claim 1 , wherein the plurality of ultrasonic transducers is divided into n areas claim 1 , each having a fan shape and having a central angle of 360°/n (n is an integer equal to or greater than 2) claim 1 , ...

Подробнее
03-01-2019 дата публикации

DEVICE FOR INSERTION INTO A BODY CAVITY, AND METHOD OF FABRICATION THEREOF

Номер: US20190000668A1
Принадлежит:

There is provided a device for insertion into a body cavity, the device includes an insertion member configured to be inserted into the body cavity, an expandable member coupled to the insertion member, the expandable member capable of being expanded to apply pressure onto tissue within the body cavity, a first member configured for storing a first endothermic reactant therein, and a second member configured for storing a second endothermic reactant therein. In particular, the first and second members are configured to, in a state of the device (e.g., compressed state), allow the first and second endothermic reactants to cooperate to effect an endothermic reaction to generate an endothermic product. Furthermore, the expandable member is configured to receive at least one of the first or second endothermic reactant and the endothermic product through a channel within the insertion member. There is also provided a method of fabricating a device for inserting into a body cavity. 1. A device for insertion into a body cavity , the device comprising:an insertion member configured to be inserted into the body cavity;an expandable member coupled to the insertion member, the expandable member capable of being expanded to apply pressure onto tissue within the body cavity;a first member configured for storing a first endothermic reactant therein; anda second member configured for storing a second endothermic reactant therein,wherein the first and second members are configured to, in a state of the device, allow the first and second endothermic reactants to cooperate to effect an endothermic reaction to generate an endothermic product, andwherein the expandable member is configured to receive at least one of the first or second endothermic reactant and the endothermic product through a channel within the insertion member.2. The device according to claim 1 , wherein the first member has stored therein the first endothermic reactant claim 1 , and the second member has stored ...

Подробнее
07-01-2016 дата публикации

ORAL PHARMACEUTICAL COMPOSITIONS OF OSPEMIFENE

Номер: US20160000732A1
Принадлежит: CADILA HEALTHCARE LIMITED

The present invention relates to pharmaceutical compositions comprising ospemifene or a pharmaceutically acceptable salt thereof having an average particle size of more than 20 microns and one or more pharmaceutically acceptable excipients comprising at least one solubility enhancing agent. The compositions of the invention may be advantageously used for the treatment or prevention of atrophy-related diseases or disorders in women, especially in women during or after the menopause. 2. The pharmaceutical composition according to claim 1 , wherein the composition comprises about 30 mg to about 90 mg of ospemifene.3. The pharmaceutical composition according to claim 1 , wherein the ospemifene has an average particle size more than 25 microns.4. The pharmaceutical composition according to claim 1 , wherein the solubility enhancing agent is present intragranularly.5. The pharmaceutical composition according to claim 1 , wherein the composition is in the form of a tablet claim 1 , a capsule claim 1 , pellets claim 1 , granules claim 1 , a sachet claim 1 , or sprinkles.6. The pharmaceutical composition according to claim 1 , wherein the pharmaceutically acceptable excipients comprise one or more of binders claim 1 , fillers claim 1 , complexing agents claim 1 , enhancing agents claim 1 , disintegrants claim 1 , lubricants claim 1 , glidants claim 1 , sweetening agents claim 1 , anti-tacking agents claim 1 , or a combination thereof.7. The pharmaceutical composition according to claim 1 , wherein the solubility enhancing agent comprises a surface active agent comprising sodium lauryl sulfate claim 1 , polysorbate 80 claim 1 , benzyl alcohol claim 1 , sorbitan monolaurate claim 1 , poloxamer 407 or combinations thereof.8. The pharmaceutical composition according to claim 7 , wherein the surface active agent comprises about 0.1 to about 6% by weight of the intra-granular composition.9. The pharmaceutical composition according to prepared by a process comprising:a) preparing a ...

Подробнее
07-01-2021 дата публикации

Applicator for Dispensing a Medical Substance and Methods Associated Therewith

Номер: US20210001100A1
Принадлежит: Syringe LLC

An applicator 270 includes a stem 174 having an axially-formed slot delivery passage 200. A slot 350 is formed transaxially through the stem 174 and is in communication with the slot delivery passage 200. An extended side wall 350b is formed on one side of the slot 350. A flat surface 354, which is formed in the stem 174, is spaced and extends angularly away from an opposite side of the slot 176 and from the extended side wall 350b to provide for direct and lateral dispensing of a cream 280 onto a tissue 242 of a patient.

Подробнее
04-01-2018 дата публикации

METHODS AND DEVICES TO PREVENT PREMATURE BIRTH

Номер: US20180001066A1
Принадлежит:

Methods and devices to affect types, proportion, quantity, distribution, or proliferation of microorganisms within a female reproductive system. 1. A method for delivering a microbial barrier to a vaginal portion of a cervix of a pregnant woman , the method comprising:visualizing the distal portion of the vagina of the pregnant woman; andapplying a barrier material over cervical epithelial tissue on the vaginal portion of the cervix while preventing the barrier material from completely obstructing a path of egress of biological materials from the uterus into the vagina.2. The method of claim 1 , wherein the barrier is applied without inserting an implant into the cervical canal.3. The method of claim 1 , wherein the barrier material is prepared by combining two or more previously separated liquid or gel-like components.4. The method of claim 3 , wherein the combined previously separated liquid or gel-like components are delivered over the cervical epithelial tissue prior to a full transformation of the combined components into a solid or substantially solid state.5. The method of claim 1 , wherein a surface of the vaginal portion of the cervix is prepared for delivery of the microbial barrier by one or more of: drying the surface claim 1 , removing bacteria from the surface claim 1 , removing mucus or fluids from the surface claim 1 , disinfecting the surface claim 1 , or applying an agent to the surface that promotes adhesion of the coating material to the surface.6. The method of claim 1 , wherein the delivered barrier material occupies a site wholly outside of the uterus and cervical canal.7. The method of claim 1 , wherein the delivered barrier material is configured not to prevent or substantially impede the evacuation of chorioamniotic fluids in the event of rupture of chorioamniotic membranes.8. The method of claim 1 , wherein the microbial barrier is delivered without disrupting a cervical mucus plug within the cervical canal.9. A method for delivering a ...

Подробнее
02-01-2020 дата публикации

Sino-Nasal Rinse Delivery Device with Agitation, Flow-Control and Integrated Medication Management System

Номер: US20200001060A1
Принадлежит: Sandler Scientific LLC

A device, a system and a method are provided to accurately apply a medically beneficial substance directly to a laterally or superiorly located paranasal sinus cavity. When the device is assembled with a solution in a reservoir, and inverted such that the reservoir is above an input apparatus and a housing, weight of the solution pushes down on a diaphragm creating a negative pressure on the diaphragm, which prevents air from entering the reservoir and prevents a liquid from flowing out of the reservoir. Applying a positive pressure to a bottom of the diaphragm causes the diaphragm to open and allows air to flow into the reservoir. When a user creates the positive pressure by exhaling air into the device the act of exhaling causes the user's choana to close. Thereby any solution introduced into the user's sino-nasal cavity will remain contained within the user's sino-nasal cavity increasing effectiveness of treatment and decreasing user discomfort including gagging, choking, and inner ear disturbance. When the positive pressure on the bottom of the diaphragm is removed, the flow of the liquid from the reservoir stops. 1. A device for delivering a solution to a sino-nasal cavity of a user , the device comprising:a reservoir container;a housing adapted to connect to the reservoir container wherein the housing has a nose tube and a grinding chamber with a filter in the housing and a plurality of grinding teeth extending perpendicular to the filter;an input apparatus adapted to connect to the housing wherein the input apparatus has a mouth piece connected to a tube and the tube is connected to a L-connector on the input apparatus; and,a mortar with a first end and a second end.2. (canceled)3. The device for delivering a solution to the sino-nasal cavity of a user of wherein the mouth piece is removably attached to a first terminal end of the tube and a diaphragm is interposed at the L-connector on the input apparatus.4. The device for delivering a solution to the sino- ...

Подробнее
02-01-2020 дата публикации

MINIATURE INGESTIBLE DEVICE

Номер: US20200001061A1
Принадлежит:

The present invention discloses multiple approaches to preventing the capsule walls and other material from interfering with the performance of an electronic device once the device is activated by surrounding fluid. In accordance with the teachings of the present invention, a miniature ingestible device (MID) may be created using excipients and films. The MID, in accordance with various aspects of the present invention, will have a coating or laminating surrounding an electronic device and separating and isolating the device from the pharmaceutical product or drug within the capsule once the capsule is ingested as well as from the capsule itself as the capsule walls begin to collapse during the disintegration process. 1. A unit including a pharmaceutical product , wherein the unit is ingestible and activated upon contact with a fluid , the unit comprising:a capsule including a wall, wherein the capsule defines a cavity for holding the pharmaceutical product and wherein the wall loses its shape and disintegrates upon contact with the fluid; and a first surface with a first portion of the partial power source;', 'a second surface with a second portion of the partial power source; and', 'a control unit for encoding the information in the current flow, wherein the control unit is electrically coupled between the first and second portions of the partial power source; and', 'a material positioned over the first portion and the second portion of the partial power source, wherein the material disintegrates upon contact with the fluid to provide physical separation between the device and the disintegrating wall of the capsule., 'a device including a partial power source located within the cavity of the capsule, wherein the device is capable of encoding information in a current flow, which occurs when the device is activated as the partial power source contacts the fluid, the device comprising2. The unit of claim 1 , wherein the material comprises an excipient material that ...

Подробнее
07-01-2021 дата публикации

Device for the dosed filling of a container with a filling material

Номер: US20210002006A1
Принадлежит: DS-Technology GmbH

A device for the dosed filling of a container with a filling material has a holding unit for holding the container and a filling unit by which a defined amount of filling material is withdrawn from a material store and transferred into the container. The filling unit has a dosing chamber. The dosing chamber is mounted displaceably alternately between a first position and in a second position. In its first position, the dosing chamber is in contact with the material store so that filling material can be transferred out of the material store into the dosing chamber. In its second position, the dosing chamber is situated above the container so that the filling material in the dosing chamber can be emptied into the container. The material store is in the form of a separate container and can be fastened detachably to the device by a fastening unit. 110.-. (canceled)1110124022. A device ( , ) for metered filling of a container () with a filling material () , comprising:{'b': 42', '40, 'a receiving unit () for receiving a container ();'}{'b': 20', '20', '2, 'a material store designed as a separate container (, .);'}{'b': 26', '26', '2', '20', '20', '2, 'a fastening unit (, .) for detachably fastening the material store (, .); and'}{'b': 22', '20', '20', '2', '40, 'a filling unit, configured to remove a defined quantity of the filling material () from the material store (, .) and transfer the defined quantity of the filling material into the container (),'}{'b': 32', '64', '66, 'wherein the filling unit comprises at least one metering chamber (, , ),'}{'b': 32', '64', '66', '32', '64', '66', '36', '68', '38', '70, 'wherein the at least one metering chamber (, , ) is displaceably mounted so that the at least one metering chamber (, , ) is present alternately in a first position (, ) and in a second position (, ),'}{'b': 36', '38', '32', '64', '66', '20', '20', '2', '22', '32', '64', '66', '20', '20', '2, 'wherein in the first position (, ) the at least one metering chamber ...

Подробнее
14-01-2016 дата публикации

Stable Pharmaceutical Package Comprising Azilsartan Medoxomil

Номер: US20160008328A1
Принадлежит: CADILA HEALTHCARE LIMITED

The present invention relates to pharmaceutical package comprising a pharmaceutical preparation comprising azilsartan medoxomil and salts thereof, and a desiccant. Also, relates to a pharmaceutical preparation comprising azilsartan medoxomil and salts thereof and a pH modifier, wherein pH modifier provides a pH range of about 5.5 to about 6.5 when dissolved or suspended in water at a concentration of 1% at 25° C. The invention also relates to processes for the preparation of such pharmaceutical preparation and use thereof for prophylaxis or treatment of circulatory diseases. 1. A pharmaceutical package comprising a pharmaceutical preparation comprising azilsartan medoxomil and salts thereof , and a desiccant.2. The pharmaceutical package as claimed in claim 1 , the pharmaceutical preparation comprising azilsartan medoxomil and salts thereof claim 1 , a pH modifier claim 1 , and a desiccant claim 1 , wherein pH modifier provides a pH range of about 5.5 to about 6.5 when dissolved or suspended in water at a concentration of 1% at 25° C.3. The pharmaceutical package as claimed in claim 1 , the pharmaceutical preparation comprising azilsartan medoxomil and salts thereof claim 1 , pH modifier and a desiccant claim 1 , wherein the composition is free of odor produced by hydrolysis of (5-methyl-2-oxo-1 claim 1 ,3-dioxol-4-yl)methyl group (i.e. claim 1 , a medoxomil group) in azilsartan.4. The pharmaceutical package as claimed in claim 1 , the pharmaceutical preparation comprising azilsartan medoxomil and salts thereof claim 1 , pH modifier and a desiccant claim 1 , wherein the said pharmaceutical preparation retains at least 80% of the potency of azilsartan medoxomil and salts thereof in the pharmaceutical composition after storage at 40° C. and 75% relative humidity for three months.5. The pharmaceutical package as claimed in claim 1 , the pharmaceutical preparation comprising azilsartan medoxomil and salts thereof claim 1 , pH modifier and a desiccant claim 1 , wherein ...

Подробнее
14-01-2016 дата публикации

PHARMACEUTICAL COMPOUNDING KIT

Номер: US20160008777A1
Принадлежит:

A kit which is useful in the preparation of a compounded pharmaceutical product is provided. A method for using such a kit to make a compounded pharmaceutical product, and a compounded pharmaceutical product are also provided. Further provided is an apparatus for use in making a compounded pharmaceutical product. 1. A kit for use in the preparation of a compounded pharmaceutical product , said kit comprising an active agent container , wherein said kit is capable of producing compounded pharmaceutical products wherein the pharmaceutically active agent can be present in said product at various dosage strengths.2. The kit according to claim 1 , wherein said kit further comprises an inactive agent container associated with said active agent container.3. The kit according to claim 2 , wherein said kit further comprises a connector means.4. The kit according to claim 2 , wherein said active agent container or said inactive agent container is in the form of a media dispenser which is capable of drawing and dispensing a metered amount of the contents therein.5. The kit according to claim 2 , wherein said kit comprises at least two inactive agent containers with one being a non-base inactive container and another being a base container claim 2 , said non-base inactive container being in the form of a media dispenser.6. The kit according to wherein said inactive agent container and said active container are chambers within a multi-chambered pouch and wherein the barrier between said containers is frangible or contains a frangible element and said kit further comprises a recipient container which is capable of drawing and dispensing metered amounts of media.7. The kit according to claim 6 , wherein said kit comprises at least two inactive agent containers with one being a non-base inactive container contained in said pouch with said active container and another being a base container which is separate from said pouch.8. The kit according to claim 6 , further comprising a ...

Подробнее
09-01-2020 дата публикации

APPARATUS AND METHODS FOR LUBRICATING DEVICES INTRODUCED INTO A BODY OF A PATIENT

Номер: US20200008664A1
Автор: Lewis Dennis
Принадлежит:

Apparatus and methods are provided for lubricating a medical device, such as a colonoscope, being introduced into a patient's body. In one embodiment, the apparatus includes a housing including a proximal surface, a distal surface, a channel extending between the proximal and distal surfaces; and a lubricant within an interior of the housing surrounding the channel such that a scope or other device inserted through the channel receives lubricant on its outer surface before introduction into a patient's body. 1. An apparatus for lubricating a medical device being introduced into a patient's body , comprising:a housing including a proximal surface, a distal surface, a channel extending between the proximal and distal surfaces; anda lubricant within an interior of the housing surrounding the channel such that a device inserted through the channel receives lubricant on its outer surface before introduction into a patient's body.2. The apparatus of claim 1 , wherein the housing comprises an annular wall surrounding the channel.3. The apparatus of claim 2 , wherein the annular wall comprises permeable material that allows lubricant from the interior to pass through the annular wall into the channel to apply lubricant to a device inserted through the channel.4. The apparatus of claim 2 , wherein the annular wall comprises a plurality of openings therethrough sized to allow lubricant from the interior to pass through the annular wall into the channel to apply lubricant to a device inserted through the channel.5. The apparatus of claim 2 , wherein the annular wall is formed from elastic material such that the annular wall may expand to accommodate different size devices being inserted through the channel.6. The apparatus of claim 1 , wherein the housing is formed from elastic material such that the channel may expand to accommodate different size devices being inserted through the channel.7. The apparatus of claim 1 , wherein the housing comprises an annular ring surrounding ...

Подробнее
08-01-2015 дата публикации

TABLET, METHOD OF PRODUCING TABLET, TABLET MANAGEMENT DEVICE, TABLET VERIFICATION DEVICE AND PROGRAM STORAGE MEDIUM

Номер: US20150010758A1
Принадлежит:

A method of producing a tablet in which an uncoated tablet is coated by a coating agent, the method including: a coating process of coating uncoated tablets with a coating agent by spray coating the coating agent onto tablets that are churned and tumbled inside a container, and drying the tablets inside the container by supplying drying air into the container and exhausting air from the container, wherein spray coating conditions, including air supply temperature, air supply rate, and spray speed, are controlled according to the weight of the coating agent with which the uncoated tablets are coated, such that the humidity of air exhausted during spray coating is within a range of from 14% RH to 30% RH. 1. A method of producing a tablet in which an uncoated tablet is coated by a coating agent , the method comprising:a coating process of coating uncoated tablets with a coating agent by spray coating the coating agent onto tablets that are churned and tumbled inside a container, and drying the tablets inside the container by supplying drying air into the container and exhausting air from the container,wherein spray coating conditions, including air supply temperature, air supply rate, and spray speed, are controlled according to a weight of the coating agent with which the uncoated tablets are coated, such that a humidity of air exhausted during spray coating is within a range of from 14% RH to 30% RH.2. The method of producing a tablet of claim 12 , wherein the spray coating conditions are controlled such that in cases in which a proportion of a weight of the coating agent to a weight of the uncoated tablets is 3.6% by weight claim 12 , a moisture content of the tablets on completion of spray coating is between 1.3% by weight and 2.3% by weight.3. The method of producing a tablet of claim 1 , wherein the spray coating conditions are controlled such that a temperature of the tablets during spray coating is 47° C. or lower.4. The method of producing a tablet of claim 1 ...

Подробнее
10-01-2019 дата публикации

Systems and Methods Related to Fluid Pumping

Номер: US20190009229A1
Принадлежит:

Systems for a plastic pump/actuator capable of containing and pumping organic solvents and lubricants and having a more desirable lubricity within the system. The system has at least two cylinders, with plungers therein, oppositely disposed from each other and configured to operably connect to a pump. 1. A reciprocating actuator assembly comprising:a first cylinder;a first plunger with a piston;a second cylinder configured to be coupled to and in fluid communication with the first cylinder;a second plunger with a piston configured to translate within the second cylinder; anda fluoropolymer coating applied within the first cylinder, within the second cylinder, and to the piston of the first plunger and the piston of the second plunger.2. The actuator assembly of claim 1 , wherein at least one of the first and second cylinders comprise cyclic olefin copolymer (COC).3. The actuator assembly of claim 1 , wherein at least one of the first and second cylinders comprise cyclo-olefin polymer (COP).4. The actuator assembly of claim 1 , wherein the first cylinder has approximately a 1 cc capacity and whereby the static friction between the first cylinder and the first piston is less than about 2.5 N.5. The actuator assembly of claim 1 , wherein the first cylinder has approximately a 3 cc capacity and whereby the static friction between the first cylinder and the first piston is less than about 4.0 N.6. The actuator assembly of further configured to be operatively coupled to a pump.7. The actuator assembly of claim 6 , wherein the first plunger has a first end and a second end claim 6 , wherein the first end of the plunger is received within the first cylinder and the second end of the plunger is received within a pump cylinder.8. The actuator assembly of claim 1 , further comprising a check valve coupled between the first cylinder and the second cylinder.9. The actuator assembly of claim 8 , wherein the check valve is configured to be removably coupled to a third cylinder ...

Подробнее
03-02-2022 дата публикации

THERAPEUTIC SUBSTANCE STORAGE AND DELIVERY

Номер: US20220032020A1
Автор: Smyth Daniel
Принадлежит:

An apparatus, including a refillable therapeutic substance delivery device including a reservoir, the reservoir being configured to be located in an adult middle ear cavity of a human recipient, wherein in some instances, the device is configured such that the reservoir is accessible through a tympanic membrane of the recipient. 1. An apparatus , comprising:a refillable therapeutic substance delivery device including a reservoir, the reservoir being configured to be located in a middle ear cavity of a human recipient.2. The apparatus of claim 1 , wherein:the device is configured such that the reservoir is accessible through a tympanic membrane of the recipient.3. The apparatus of claim 1 , wherein:the device is configured such that the device is attachable to a tympanic membrane while functioning ossicles are attached thereto.4. The apparatus of claim 3 , wherein:the device is configured so as to limit any damping of the tympanic membrane due to the attachment of the device thereto such that a damping ratio of the tympanic membrane is reduced by no more than 25% relative to that which would be the case in the absence of the attachment.5. The apparatus of claim 1 , wherein:the device includes a grommet attachable to a tympanic membrane through which the reservoir can be accessed to refill the reservoir.6. The apparatus of claim 1 , wherein:the device is configured to deliver therapeutic substance from the reservoir into a cochlea of the recipient across a round window membrane.7. The apparatus of claim 1 , wherein:the device is configured to extend from a location at least proximate a tympanic membrane to a round window niche of a cochlea.8. (canceled)9. An apparatus claim 1 , comprising:a refillable therapeutic substance delivery device securable to a round window niche of a recipient.10. The apparatus of claim 9 , wherein:the therapeutic substance delivery device is refillable while the therapeutic substance delivery device is secured to the round window niche.11. ...

Подробнее
03-02-2022 дата публикации

ULTRA-SHARP MICRONEEDLE

Номер: US20220032023A1
Принадлежит:

A microneedle having a body including a base, shaft and pointed tip, and at least one lumen disposed within the shaft. The lumen having an opening that is offset from the tip and open to the exterior of the microneedle. 1. A microneedle comprising:a base disposed at a proximal end of the microneedle body and a tip disposed at the distal end of the microneedle body, a shaft having a longitudinal body disposed between the base and the tip, wherein the base has a width greater than the width of the tip,at least one lumen defining a channel providing fluid communication and passage disposed within at least the shaft of the microneedle body, andan opening defined at the distal end of the lumen and at a loci of the shaft, wherein the opening is off-set from the central longitudinal axis of the tip.2. The microneedle of claim 1 , wherein the at least one lumen has a body extending through the base to the shaft of the microneedle.3. The microneedle of claim 1 , wherein the at least one lumen has a body that terminates proximate to the tip.4. The microneedle of claim 1 , wherein the base is configured to mount a medical instrument.5. The microneedle of claim 4 , wherein the medical instrument is a syringe.6. The microneedle of wherein the base has a width greater than the shaft.7. The microneedle of claim 1 , wherein the base claim 1 , shaft and tip are integral to form microneedle body.8. The microneedle of claim 1 , wherein the tip includes a sharp claim 1 , pointed apex.9. The microneedle of claim 1 , wherein the offset is about 25 microns.10. The microneedle of claim 1 , wherein the tip has a 500 nm radius of curvature.11. The microneedle of claim 1 , wherein the shaft is about 350 microns.12. The microneedle of claim 1 , wherein the at least one lumen is only one sole lumen.13. The microneedle of claim 1 , wherein the at least one lumen is two separate lumens.14. The microneedle of claim 1 , wherein the maximum tip diameter is about 10-20 microns.15. The microneedle of ...

Подробнее
21-01-2016 дата публикации

Enhanced drug delivery pill

Номер: US20160015648A1
Автор: Yossi Gross, Zev Sohn
Принадлежит: Rainbow Medical Ltd

An ingestible pill includes a coating configured to dissolve in a small intestine; a core, which includes a medication-delivery element, which (a) has a compressed shape when disposed within the coating, and (b) is configured to assume, after the coating dissolves, an expanded shape; a medication; and a mucoadhesive. When unconstrained in the expanded shape, the medication-delivery element (a) is shaped so as to define first and second surfaces on opposite sides of the medication-delivery element, which have respective outer perimeters, which surround respective spaces of the respective surfaces, which spaces have respective greatest dimensions equal to between 2 and 10 cm, and each of which spaces has an area equal to at least 50% of the square of the greatest dimension; and (b) has an average thickness between the first and the second surfaces of less than 6 mm. Each of the medication and the mucoadhesive at least partially coats the first surface.

Подробнее
17-01-2019 дата публикации

IMPLANT DEVICE, TOOL, AND METHODS RELATING TO TREATMENT OF PARANASAL SINUSES

Номер: US20190015643A1
Принадлежит:

An implant device is configured to be implanted in a fistula to fluidly connect the lacrimal apparatus and a paranasal sinus. A surgical tool has an implant the implant device mounted on a carrier. Various methods involve a fistula between the lacrimal apparatus and a paranasal sinus. A kit includes an entry device for use to form a fistula and an implant tool for use to implant an implant device following formation of a fistula. 1128-. (canceled)129. A kit for treatment of sinusitis through an implant device for implantation in a human to provide a fluid connection between a location in a lacrimal apparatus to a paranasal sinus through a fistula formed between the lacrimal apparatus and the paranasal sinus to provide direct medical access through the implant device from the lacrimal apparatus to the paranasal sinus , the kit comprising:a first surgical tool having a first working member configured to form an initial fistula; a proximal end at a first longitudinal end of the implant device;', 'a distal end at a second longitudinal end of the implant device that is longitudinally opposite the first longitudinal end;', 'a conduit extending from adjacent the proximal end to adjacent the distal end;', 'a first internal passage extending between the proximal end and the distal end and through the conduit, the first internal passage having a first end open at the proximal end and a second end open at the distal end; and', 'a length of the implant device longitudinally along the implant device between the proximal end and the distal end in a range of from 8 millimeters to 50 millimeters; and', 'wherein the conduit is constructed of polymeric material having a durometer (Shore A) in a range of from 50 to 100, and the implant device is configured to be implanted to fluidly connect the lacrimal apparatus to the paranasal sinus through the first internal passage of the implant device with the proximal end of the implant device disposed in the lacrimal apparatus with the first ...

Подробнее
21-01-2021 дата публикации

FORMULATIONS OF (S)-3-AMINO-6-METHOXY-N-(3,3,3-TRIFLUORO-2-HYDROXY-2-METHYLPROPYL)-5-(TRIFLUOROMETHYL)PICOLINAMIDE

Номер: US20210015804A1
Принадлежит:

Provided herein are compounds and pharmaceutical compositions useful for treating bronchiectasis, chronic obstructive pulmonary disorder, cystic fibrosis, chronic bronchitis or asthma comprising administering to a subject in need thereof a therapeutically effective amount of a compound or pharmaceutical composition described herein. 332.-. (canceled)33. A method for the treatment of bronchiectasis claim 1 , chronic obstructive pulmonary disorder claim 1 , cystic fibrosis claim 1 , chronic bronchitis or asthma claim 1 , comprising administering the pharmaceutical composition of to a subject in need thereof.34. A method for promoting mucus clearance in a subject with bronchiectasis claim 1 , chronic obstructive pulmonary disorder claim 1 , cystic fibrosis claim 1 , chronic bronchitis or asthma comprising administering the pharmaceutical composition of any one of to a subject in need thereof.3541.-. (canceled)42. A method for the treatment of bronchiectasis claim 1 , chronic obstructive pulmonary disorder claim 1 , cystic fibrosis claim 1 , chronic bronchitis or asthma claim 1 , comprising administering (S)-3-amino-6-methoxy-N-(3 claim 1 ,3 claim 1 ,3-trifluoro-2-hydroxy-2-methylpropyl)-5-(trifluoromethyl)picolinamide to a subject in need thereof claim 1 , wherein (S)-3-amino-6-methoxy-N-(3 claim 1 ,3 claim 1 ,3-trifluoro-2-hydroxy-2-methylpropyl)-5-(trifluoromethyl)picolinamide is administered to the subject without a high fat meal.43. A method for promoting mucus clearance in a subject with bronchiectasis claim 1 , chronic obstructive pulmonary disorder claim 1 , cystic fibrosis claim 1 , chronic bronchitis or asthma comprising administering (S)-3-amino-6-methoxy-N-(3 claim 1 ,3 claim 1 ,3-trifluoro-2-hydroxy-2-methylpropyl)-5-(trifluoromethyl)picolinamide to a subject in need thereof claim 1 , wherein (S)-3-amino-6-methoxy-N-(3 claim 1 ,3 claim 1 ,3-trifluoro-2-hydroxy-2-methylpropyl)-5-(trifluoromethyl)picolinamide is administered to the subject without a high fat ...

Подробнее
15-01-2015 дата публикации

ENEMA DISPENSER

Номер: US20150018778A1
Автор: Cox Charles H.
Принадлежит:

An enema includes a liquid in a dispenser having a bottle, a nozzle attached to the bottle, and a valve. The valve may be a membrane having a slit and a thickness of at most 0.90 mm. The valve may be attached to the bottle or it may be attached to the nozzle. The enema can be administered more easily, with a lower amount of force. A method of bowel cleansing includes inserting the enema into a rectum and applying a compression force to the enema bottle. 126-. (canceled)27. A dispenser , comprising:a bottle comprising a bottle opening;a nozzle, attached to the bottle at the bottle opening, and comprising a proximal opening, a distal opening, and a lumen between the proximal opening and the distal opening; anda valve, comprising a membrane having a slit and a thickness from 0.05 to 0.90 mm.28. The dispenser of claim 27 , wherein the valve is attached to the bottle opening.29. The dispenser of claim 27 , wherein the bottle further comprises a body and a neck between the body and the opening.30. The dispenser of claim 29 , wherein the valve is attached to the neck.31. The dispenser of claim 27 , wherein the valve is attached to the nozzle and extends across the lumen.32. The dispenser of claim 27 , wherein the valve prevents liquid flow from the distal opening into the bottle.33. An enema claim 27 , comprising:a bottle comprising a bottle opening;a nozzle, attached to the bottle at the bottle opening, and comprising a proximal opening, a distal opening, and a lumen between the proximal opening and the distal opening;a liquid in the bottle; anda valve, comprising a membrane having a slit and a thickness from 0.05 to 0.90 mm.34. The enema of claim 33 , wherein the valve is attached to the bottle opening.35. The dispenser of claim 33 , wherein the bottle further comprises a body and a neck between the body and the opening.36. The dispenser of claim 35 , wherein the valve is attached to the neck.37. The dispenser of claim 33 , wherein the valve is attached to the nozzle and ...

Подробнее
26-01-2017 дата публикации

NASAL AEROSOL DELIVERY SYSTEM

Номер: US20170020383A1
Принадлежит:

A nasal delivery device can include a nasal prong and an activation member. The nasal prong can comprises an opening at a top and bottom portion of the prong to allow for the passage of an aerosolized treatment agent through the nasal prong. The activation member can be positioned on the nasal delivery device at a location that is spaced apart from the subject's oral cavity when the nasal prong is received into the nostril of the subject. The activation member can be configured to detect a desired exhalation state of the subject and upon detection of the desired exhalation state, the activation member activates the delivery of the aerosolized treatment agent. 1. A nasal delivery device for delivering an aerosolized treatment agent to the subject , wherein the nebulizing device is configured to aerosolize the treatment agent and generally deliver the aerosolized treatment agent along a delivery axis into the nostril of the patient , further comprising an alignment device for aligning the delivery axis of the aerosolized treatment agent with a nasal airway of the subject.2. The nasal delivery device of claim 1 , wherein the alignment device comprises a light source and a light detector that are generally coaxially aligned claim 1 , the light detector detecting an amount of light reflected from a surface in the subject's nostril.3. The nasal delivery device of claim 2 , wherein upon detection of an amount of reflected light that is greater than a predetermined amount claim 2 , the alignment device indicates that the delivery axis of the aerosolized treatment agent is not aligned with the nasal airway claim 2 , and upon detection of an amount of reflected light that is less than a predetermined amount claim 2 , the alignment device indicates that the delivery axis of the aerosolized treatment agent is aligned with the nasal airway.4. The nasal delivery device of claim 1 , wherein the alignment device comprises a light source that directs light into the nostril of the ...

Подробнее
28-01-2016 дата публикации

SEPARABLE CAPSULE

Номер: US20160022593A1
Принадлежит: Capsugel Belgium NV

The present disclosure relates to a separable hard capsule for containing a medication. The capsule may be opened by finger force and used, for example, by pediatric and geriatric patients. 1. A two-piece releasable hard capsule comprising:a first part having an open end, a closed end, insertion axis, and a first connection unit having a lock area comprising a plurality of first coupling elements;a second part having a second connection unit, wherein the second connection unit has an engagement area comprising a second coupling element, the engagement area being configured to engage with the lock area when the second part is fully inserted in the first part to form a connection releasable by a finger force, wherein the plurality of first coupling elements comprise protrusions substantially elongate in shape comprising an elongated axis running parallel to an insertion axis and comprising a restriction edge perpendicular to the insertion axis.2. A capsule according to claim 1 , wherein the finger force is between about 30 grams and about 200 grams.3. (canceled)4. A capsule according to claim 1 , wherein the second coupling element comprises an indentation having a recessed ring claim 1 , preferably wherein the recessed ring has an asymmetric cross-section along the insertion axis.5. (canceled)6. A capsule according to claim 1 , wherein the first coupling elements have a depth of about 50 microns to about 200 microns.7. A capsule according to claim 1 , wherein the first connection unit further comprises a prelock area comprising a plurality of third coupling elements claim 1 , and wherein the engagement area is configured to engage with the prelock area when the second part is partially inserted in the first part to form a prelock releasable connection.8. A capsule according to claim 1 , wherein the restriction edge is configured to restrict insertion depth when inserting the second part into the first part for engaging a prelock releasable connection.9. (canceled)10. ...

Подробнее
28-01-2016 дата публикации

Dosage Form Comprising Crizotinib

Номер: US20160022661A1
Автор: PROHL Sabine, STEFAN Ralph
Принадлежит:

The invention relates to a method of preparing a tablet, preferably a tablet for immediate release and having a high drug load, containing crizotinib in form of the free base and lubricant, both in specific amounts. The invention further relates to a tablet obtainable by said method. 1. A method for preparing a tablet comprising the steps ofi) providing crizotinib free base (a) and lubricant (b);ii) blending or dry-compacting the components from step i); andiii) processing the mixture from step ii) into a tablet;wherein the tablet comprises 20 to 70 wt % crizotinib free base and 5 to 25 wt % lubricant, based on the total weight of the tablet.2. The method according to claim 1 , wherein the crizotinib free base (a) is present from 40 to 65 wt % claim 1 , based on the total weight of the tablet.3. The method according to claim 1 , wherein the crizotinib has an average particle size (D50) of 0.5 to 150 μm.4. The method according to claim 1 , wherein the weight ratio of crizotinib (a) to lubricant (b) is from 2:1 to 10:1.5. The method according to claim 1 , wherein the lubricant produces an R-value from 0.90 to 0.99.6. The method according to claim 1 , wherein the lubricant comprises an organic residue containing 10 to 24 carbon atoms.7. The method according to claim 1 , wherein lubricant is amphiphilic.8. The method according to claim 1 , wherein the tablet further comprises one or more pharmaceutical excipients.9. The method according to claim 1 , wherein the tablet comprisesa) 20 to 75 wt % crizotinib free base,b) 5 to 25 wt % lubricant,c) 0.1 to 3 wt % glidant,d) 5 to 35 wt % filler,e) 0 to 15 wt % disintegrant, andf) 0 to 15 wt % binder,and wherein the wt % are based on the total weight of the dosage form.10. The method according to claim 1 , wherein the tablet provides immediate release of crizotinib.11. The method according to claim 1 , wherein step i) includes preparing a pre-blend comprising crizotinib and lubricant.12. The method according to claim 1 , wherein ...

Подробнее
10-02-2022 дата публикации

Pharmaceutical Composition of Chlordiazepoxide and Clidinium Combination

Номер: US20220040196A1
Принадлежит: Jubilant Pharma Holdings Inc.

The present invention relates to a stable pharmaceutical composition comprising a combination of chlordiazepoxide hydrochloride and clidinium bromide and one or more pharmaceutically acceptable excipients, wherein the composition is in the form of solid oral dosage forms like capsule and sachet. The technical challenges like undesirable impurities in dosage form were successfully controlled by using: a) low moisture excipients; and b) formulation development under controlled temperature and controlled humidity conditions. The formulations as per the present invention are stable and exhibit desired pharmaceutical technical attributes like assay and dissolution. The prepared formulations are useful for the treatment of gastrointestinal disorders and various other therapeutic indications as described herein. 1. A stable pharmaceutical composition comprising:a) about 0.01% to about 10% by weight of chlordiazepoxide hydrochloride;b) about 0.01% to about 10% by weight of clidinium bromide;c) about 5% to about 90% by weight of one or more low moisture excipients;d) about 0.5% to about 85% by weight of one or more other pharmaceutically acceptable excipients andwherein the ratio of chlordiazepoxide hydrochloride, clidinium bromide, and the low moisture excipient ranges from about 1:0.5:3 to about 1:0.5:35.2. The stable pharmaceutical composition according to claim 1 , wherein the low moisture excipients are free of peroxide.3. The stable pharmaceutical composition according to claim 1 , wherein the low moisture excipients are selected from lactose anhydrous claim 1 , corn starch claim 1 , silicified microcrystalline cellulose claim 1 , mannitol claim 1 , sodium carboxymethyl cellulose claim 1 , or mixtures thereof.4. The stable pharmaceutical composition according to claim 1 , wherein the particle size of the chlordiazepoxide hydrochloride and clidinium bromide is having Dvalue less than about 100 μm.5. The stable pharmaceutical composition according to claim 1 , wherein ...

Подробнее
26-01-2017 дата публикации

FEEDING ASSEMBLY TO FILL CAPSULES OR THE LIKE WITH AT LEAST TWO PRODUCTS, IN PARTICULAR PHARMACEUTICAL PRODUCTS, IN GRANULES

Номер: US20170021949A1
Автор: Nannetti Davide
Принадлежит:

The bottom of a capsule is filled with at least two products contained in respective annular rotating containing tanks, which are mounted concentrically, and have a plurality of pairs of radially aligned filling holes; the filling holes of each pair of filling holes being associated with a relative closing device, which is selectively movable between a closing position of both filling holes, a first opening position of one of the two filling holes, and a second opening position of the other filling hole. 122934314616226113221514617236222422232422233022232223. Feeding assembly to fill capsules () or the like with at least two products , in particular pharmaceutical products in granules , each capsule ( comprising a respective bottom () and a respective lid () to close the bottom () , the feeding assembly comprising a first containing tank () , which houses , on the inside , a first product , has an annular shape , is mounted so as to rotate around a rotation axis () , and is delimited by a bottom wall () provided with a plurality of first filling holes () uniformly distributed around the rotation axis (); and a pocket conveyor () to move forward , in sequence , a plurality of bottoms () in phase , each with a relative first filling hole (); and being characterised in that it comprises , furthermore , a second containing tank () , which houses , on the inside , a second product , has an annular shape that is concentric to the first containing tank () , is mounted so as to rotate around the rotation axis () , and is delimited by a bottom wall () provided with a plurality of second filling holes () , which are uniformly distributed around the rotation axis () , each defining , together with a corresponding first filling hole () , a pair () of filling holes ( , ); and , for each pair () of filling holes ( , ) , a respective closing device () , which is selectively movable between a closing position of both the filling holes ( , ) , a first opening position of the first ...

Подробнее
24-01-2019 дата публикации

METHOD FOR THE PRODUCTION OF A PHARMACEUTICAL DELIVERY SYSTEM

Номер: US20190022012A1
Принадлежит:

The present invention relates to a method for producing a pharmaceutical delivery system, the use of a surface-reacted calcium carbonate for improving the friability of a pharmaceutical delivery system as well as for improving the flowability of a pharmaceutical delivery system and a pharmaceutical delivery system obtained by the method. 1. A method for producing a pharmaceutical delivery system , comprising the steps of:a) providing surface-reacted calcium carbonate, which is a reaction product of natural ground or precipitated calcium carbonate with carbon dioxide and one or more acids in an aqueous medium, wherein the carbon dioxide is formed in situ by the acid treatment and/or is supplied from an external source;b) providing at least one pharmaceutically active agent or pharmaceutically inactive precursor thereof;c) providing at least one formulating aid;d) mixing the surface-reacted calcium carbonate of step a), the at least one pharmaceutically active agent or pharmaceutically inactive precursor thereof of step b) and the at least one formulating aid of step c); ande) compacting the mixture obtained in step d) by means of a roller compacter at a compaction pressure in the range from 4 to 20 bar; andf) compacting the roller compacted mixture obtained in step e) for obtaining the pharmaceutical delivery system.2. The method of claim 1 , wherein the natural ground calcium carbonate is selected from calcium carbonate containing minerals selected from the group comprising marble claim 1 , chalk claim 1 , dolomite claim 1 , limestone and mixtures thereof; or the precipitated calcium carbonate is selected from the group comprising precipitated calcium carbonates having aragonitic claim 1 , vateritic or calcitic mineralogical crystal forms and mixtures thereof.3. The method according to claim 1 , wherein the surface-reacted calcium carbonate{'sup': 2', '2', '2', '2', '2', '2', '2', '2', '2', '2, 'a) has a BET specific surface area of from 20.0 m/g to 200.0 m/g, ...

Подробнее
23-01-2020 дата публикации

MANUFACTURING METHOD FOR SOFTGEL CAPSULE CONTAINING SOLID AND LIQUID FORMULATIONS AS CORE INGREDIENT

Номер: US20200022874A1
Принадлежит:

The present invention relates to a manufacturing method for softgel capsule containing solid and liquid formulations as core ingredient, wherein at least one pharmaceutical drug can be included in both solid formulation and liquid formulation. More particularly, this invention relates to a softgel capsule wherein liquid formulation, for example, solution and/or suspension as well as solid formulation, for example, tablet, pellet and/or sustained release dosage are present as core ingredient and its manufacturing method. 1. A manufacturing method for a softgel capsule containing solid and liquid formulations as core ingredients comprising the steps of:i) supplying a first gelatin sheet from a first gelatin cooling drum to an upper surface of a left side die roll via a first transportation roller;ii) supplying a second gelatin sheet from a second gelatin cooling drum to an upper surface of a right side die roll via a second transportation roller;iii) transferring and inserting the solid formulation from only one solid formulation supply shooter into only one place of pocket formed on a reduced pressure peripheral surface of only the right side die roll via only one solid formulation transferring roller;iv) injecting the liquid formulation at an injection and sealing part located at the contacting place of the left side die roll and the right side die roll just under a central portion of a wedge via a central liquid injection passage; and v) forming the softgel capsule including solid and liquid formulations inside, by heat pressing, cutting off and sealing the first and the second gelatin sheets;wherein said manufacturing method further comprises:(a) supplying the first gelatin sheet from a peripheral surface of the left side die roll just under the contacting surface of a wedge segment;(b) supplying the second gelatin sheet on which only one place of pocket is formed from the peripheral surface of only the right side die roll just under the contacting surface of the ...

Подробнее
23-01-2020 дата публикации

Rupture-Stable Gelatin Filled Capsules and Manufacturing Thereof

Номер: US20200022920A1
Принадлежит:

The present invention relates to a rupture-stable gelatin filled capsule, produced from xylose cross-linked gel masses. The xylose cross-linked masses are made from a 0.01%-2% xylose solution combined with gelatin masses. The gelatin masses may be produced from gelatin of bovine, pork, fish, chicken, duck, or other poultry. The xylose solutions and gelatin masses are then mixed at temperatures from 135-200° F. and yield viscosities from 10,000-16,000 cps, creating a capsule which can be resistant to rupture in gastric digestives, but which will then rupture after a time period within the intestinal tract. 1. A rupture-stable gelatin filled capsule , comprising xylose cross-linked gel masses wherein the xylose cross-linked masses are comprised of 0.01%-2% xylose solutions and gelatin masses , and wherein the xylose solutions and gelatin masses are mixed at temperatures from 135-200° F. and yield viscosities from 10 ,000-16 ,000 cps.2. The rupture-stable gelatin filled capsule as in claim 1 , comprised of 075%-1.25% xylose solutions.3. The rupture-stable gelatin filled capsule of claim 1 , wherein the mixing temperature is within 150-200° F.4. The rupture-stable gelatin filled capsule of claim 1 , wherein the xylose solution is prepared from xylose sugars claim 1 , such as D-xylose claim 1 , L-xylose claim 1 , or DL-xylose.5. The rupture-stable gelatin filled capsule of claim 1 , wherein the gelatin masses comprise 8%-27% glycerin claim 1 , 21-66% gelatin claim 1 , and 17-53% water.6. The rupture-stable gelatin filled capsule of claim 1 , wherein the gelatin masses comprise 17.5% glycerin claim 1 , 43.5% gelatin claim 1 , and 35% water.7. The rupture-stable gelatin filled capsule of claim 1 , wherein the gelatin masses are of bovine claim 1 , pork claim 1 , fish claim 1 , chicken claim 1 , duck claim 1 , or other poultry origin.8. The rupture-stable gelatin filled capsule of claim 1 , wherein the capsule contains nutraceutical ingredients.9. The rupture-stable gelatin ...

Подробнее
02-02-2017 дата публикации

Device for Reducing Effect and Symptomologies of Bruxism and/or Morsicatio Buccarum

Номер: US20170027664A1
Автор: Dority John B.
Принадлежит:

The present invention is a device for reducing or minimizing the symptoms and/or effects of bruxism and/or morsicatio buccarum comprising a single-piece main body having an approximately U-shaped cross section that fits over one or more teeth. The body has an upper surface, a lower surface and a descending skirt one on either side of said main body and parallel to one another. Each of the descending skirts has an interior side, an exterior side, an top portion and a bottom portion. The top portion is integral to the side of the main body and is narrower in width then the bottom portion. The device is affixed to the tooth or teeth through the compression force produced by and between the descending skirts. 1. A device for reducing or minimizing the symptoms and/or effects of bruxism and/or morsicatio buccarum comprising:a single-piece main body having an approximately U-shaped cross section, said body having an upper surface, a lower surface and a descending skirt one on either side of said main body and about parallel to each other wherein each of said descending skirts have an interior side, an exterior side, an top portion and a bottom portion wherein said top portion is integral to said side of said main body and the distance between the top portion of said descending skirts is equal to or wider in width then said bottom portion.2. The device according to claim 1 , wherein the distance between said upper surface and said lower surface of said main body ranges from approximately 1 mm to approximately 10 mm.3. The device according to claim 1 , wherein the distance between said upper surface and said lower surface of said main body ranges from approximately 3 mm to approximately 8 mm.4. The device according to claim 1 , wherein the distance between said upper surface and said lower surface of said main body ranges from approximately 4 mm to approximately 6 mm.5. The device according to claim 1 , wherein said single-piece main body covers at least one tooth.6. The ...

Подробнее
04-02-2016 дата публикации

FLUID VALVE AND FLUID CONNECTION SYSTEM

Номер: US20160030287A1
Автор: AYDIN Tolga

The invention relates to a fluid valve and fluid connection system, comprising a casing having a chamber with a first internal connection element and a first external connection element; comprising a first movable valve element in the chamber; and comprising an actuating element which has a fluid communication system with a second internal connection element and a second external connection element; wherein the first internal connection element cooperates with the second internal connection element and the valve element to establish or block a fluid connection between the first and second external connection elements. 1. A fluid valve and fluid connection system comprising a housing having a receiving chamber with a first internal connection element and with a first external connection element , comprising a first movable valve element arranged in the receiving chamber , and comprising an actuating element , which has a fluid communication system with a second internal connection element and with a second external connection element , wherein the first internal connection element cooperates with the second internal connection element and the valve element in order to establish or to block a fluid connection between the first and the second external connection elements.2. The fluid valve and fluid connection system as claimed in claim 1 , wherein the actuating element can be moved relative to the housing and can adopt a first position claim 1 , in which the fluid connection between the first and the second external connection elements is blocked claim 1 , and can adopt a second position claim 1 , in which the fluid connection between the first and the second external connection elements is established.3. The fluid valve and fluid connection system as claimed in claim 1 , wherein the actuating element has means that cooperate with means of the housing in order to define the first and the second positions.4. The fluid valve and fluid connection system as claimed in ...

Подробнее